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1. INTRODUCTION
1.1. Cancer
Cancer is one the most common disease world-wide and is caused due to abnormal
growth of cells in a particular tissue, which can either stay in the same region or the cells can
disburse throughout the body via blood. Unlike normal cells that follow orderly growth,
division, and death, cancer cells continue to grow and divide causing the development of
uncontrollable masses of abnormal cells[2]. These cells may interfere with the normal bodily
function and take up nutrients and resources from healthy cells, leading to death. In such
conditions when the cancerous cells invade into healthy cells and tissues through its
progression, it is said to be have metastasized, and the condition is referred to as metastasis [3].
The primary goal of most of the researchers and physicians in the field has been the early
detection of cancer, which may prevent the disease from being malicious and makes the cancer
treatment more effective. Imaging techniques such as X-ray, computed tomography (CT),
magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and ultrasound
scans are often used to detect a tumor location and the damage that it may have caused in the
affected organ.
1.2. Clinical Imaging Modalities
Medical imaging is widely applied in clinical practice referring to the in vivo
visualization of images of internal organs of human body. These imaging modalities are used to
obtain biological functioning and to measure quantitatively the anatomical and physiological
information for clinical and medicinal applications[4]. In particular, imaging techniques have
been often used for the diagnosis and prognosis of tumor growth and it metastasis in a human
body. Furthermore, practical application of these medical-imaging can allow early detection of
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cancerous cells with improved treatment selection. There are plethora of imaging modalities that
being used for medical images including X-rays, MRI, CT, PET, Ultrasound, near infrared
(NIR), fluorescent imaging of green fluorescence proteins (GFP), Optical Imaging, and
Magnetic resonance spectroscopy (MRS).Each of these techniques has their advantages and
drawbacks for obtaining physiological and functional information as described in Table 1.1[4].
Various imaging modalities such as X-ray, Positron Emission Tomography (PET), Computed
Tomography (CT), Near Infra-Red (NIR), MRI or ultrasound have been utilized for further
advancements in the field. These techniques are well studied and explored by the researchers
and clinicians. Each has its advantages and disadvantages based on their applications. Optical
imaging techniques such as NIR and fluorescence have high sensitivity but lower solution with
the lack of deep penetration whereas spectral imaging such as MRI, or PET/SPECT has much
deeper penetration. These fluorescent techniques are often used intraoperative medical
applications.
Some of the techniques, like X-ray and CT, are used for scanning solid organs, such as
bones. However, they use gamma-emitting radioisotopes, which pose dose- dependent risks that
prevent further applications for prognosis especially for children. These imaging techniques are
not sensitive to soft tissues where cancerous cells reside. PET is another commonly used
method for the diagnosis; renders three-dimensional images using radio nuclei tracers
generating detectable gamma emissions. PET/SPECT both has high sensitivity and depth
penetration; however, they use harmful irradiation and have limited resolution. Ultrasound
(does not use radiation) is also widely used for in vivo application, but has limited depth
penetration and resolution. Unlike PET and CT, MRI is a noninvasive imaging modality that
does not use harmful ionizing radiation to generate two-dimensional and three-dimensional
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images of a thin slice through particular regions of the body. In contrast to X-ray, CT, and
ultrasound, MRI is not limited to number of scans of an entire body. Along with these
properties, MRI also allows for an excellent resolution between normal tissues and cancerous
tissues with soft tissue enhancement. Although MRI has no limitation for the depth of tissue
penetration, it has low sensitivity and requires the use of a contrast agent that interacts with
water proton to increase relaxivity and obtain better images with increased signal-to-noise ratio.
Hence, our goal in the development of MRI contrast agents can further enable the medical
imaging for early diagnosis and prognosis of cancer. Furthermore, engineering MRI contrast
agents with targeted against cancer biomarkers, we can achieve desired sensitivity and
specificity and open a new horizon in medical imaging[5, 6].
1.3. Cancer Biomarkers and Targeted Molecular Imaging
Cancer cells tend to express a high level of specific cellular receptors as compared to the
normal cells. Some cancerous cells are known to have specific receptors that are overexpressed, and these receptors are used as biomarkers to detect the growth of tumor (Figure
1.1).Much research has been done on cancer biomarkers. Analyzing the cancer biomarkers helps
the researcher to understand the diagnosis, prognosis and invasiveness of cancer. There are
some cancer receptors that are well known and specific to cancer types(Figure1.2)[7]. For
example, the HER family members, epidermal growth factor receptors (EGFR) and HER2 are
transmembrane proteins playing a crucial role in a network of multi-layered signal, transduction
pathway that results in activation of cellular response such as differentiation, growth and
survival, and cell motility[8]. These receptors have relatively low level of expression on normal
cells; however, they are overly expressed in variety of human tumors including non-small-cell
lung cancer, pancreatic cancers, prostate cancer, and brain cancer [9, 10]. HER2 receptors are
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known to overly express on 20 -30 % of breast cancer and can aggressively metastasize to other
organs[8, 11]. EGFR and HER2 receptors are significant prognostic biomarkers, so their
signaling pathways during the progression of the disease are studied to understand the
mechanistic basis of cancer [10].
Gastrin-releasing protein receptor (GRPR) belongs to the G protein-coupled receptor
family that has a typical seven-transmembrane domain, and which is frequently found in
pancreas; it is mostly absent in other organs of the body [12]. GRPR is found to have
abnormally high expression levels in prostate cancer, gastric cancer, non-small-cell lung cancer,
and breast cancer cells compared to normal cells.[13]Furthermore, GRPR appears to have
relatively high, (almost 100 %) expression on prostate cancer as compared to healthy prostate
cells. Therefore, GRPR is widely studied as a biomarker to target cancerous cells. Tracking
down the mechanism of cancer progression using biomarkers is a new emerging field that
provides answers with improved specificity and sensitivity form any questions in disease
diagnosis and targeted treatment. One of the goals of this thesis is to develop a GRPR and
bombesin-targeted contrast agent for early diagnosis and prognosis of prostate cancer cells (a
detailed explanation can be found in Chapter 3).
Molecular imaging has become a prominent aspect in the direction of cancer diagnosis
and effective treatment. Molecular imaging is a technique that probes biomarkers including
specific cell surface receptors or surroundings in order to generate in vivo images. This imaging
technology combines the biological process with advanced physical and radiological techniques
to capture images of various disease pathways at minute cellular levels[14]. The substantial
amount of efforts has been directed at developing a non-invasive, high-resolution, in vivo
imaging technology by many researchers. Such profound technology can be successfully used
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to detect and monitor diseases at an early stage and help us understand its fundamental process.
Recent advancements in molecular imaging monitors drug treatment to target disease
progression by imaging through ligand receptors on cellular surfaces or using monoclonal
antibodies to target receptors [15, 16]. This study can be further performed using he in vivo
mechanism of peptide receptor for targeting cancer in hope to better understand the
differentiation in diagnosis and monitoring of therapies using biomarker targeted molecular
imaging[17]. In this thesis study, we will further develop MRI contrast agents with cancer
biomarker targeting capabilities to increase specificity and sensitivity moving toward the
clinical applications for early diagnosis.

Figure 1.1Illustration of various biomarkers expressed under cancerous environment.
Each of these biomarkers plays a critical role in functioning and development of cells.
However, these receptors tend to express at higher level under cancerous environment and
are specific to the type of cancer, hence are referred to as biomarkers. These biomarkers
are often studied for the mechanism, diagnosis and prognosis of cancer.
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Figure 1.2 Biomarkers that are recognized by FDA considering its sensitivity and
specificity in molecular imaging. Adapted from the reference with permission [7]

6

Table 1.1List of current Clinical imaging techniques: comparing the advantages and disadvantages

*Adapted and modified with permission from the reference [4]
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1.4. Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging, developed from the basic principles of nuclear magnetic
resonance, is an important medical imaging technique that can give biological, chemical and
functional information about a body. MRI is one of the most powerful imaging techniques that
provide non-invasive diagnostic methods in current clinical and research field. MRI is a
promising technique due to its significant ability to generate three-dimensional images of the
soft tissues with in-depth tissue penetration. MRI measures the magnetic properties of water
hydrogen within an external magnetic field (B0), as they interact with radio frequency (Rf) with
electronic, magnetic waves. MRI thus detects signals generated by hydrogen atoms, which are
abundant in the form of water molecules comprising 70 % of human body, as the signal remain
uninfluenced by other predominant biological compounds such as 12C, 16O, and 14N[18, 19].
As shown in Figure 1.4, MRI images are generated by relaxation rates of hydrogen
nuclei containing single proton, which undergoes multiple spin states such as magnetic and
angular moment, generating magnetization properties. Nuclei containing even number of
protons and neutrons have zero net magnetization (12C or
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N) due to cancellation of paired

spin, while hydrogen nuclei containing an odd number of protons, have an angular momentum
with net spin of ±1/2 (magnetic quantum number) that are unpaired, giving rise to magnetic
properties due to rotational and vibrational motion. Hydrogen nuclei are in a low energy state
and have random orientation in the absence of external magnetic field (B0). However, during the
MRI scans, these hydrogen nuclei present in various organs of the body aligns in the presence
of the magnetic field generating an overall net magnetization. In general, when a uniform
external magnetic field (B0) is applied, the hydrogen nuclei align either parallel or anti- parallel
to the magnetic field creating a net magnetic moment (M) (Figure 1.3). Under the external
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magnetic field, these nuclei rotate or precess along the applied magnetic field and the frequency
at which the nuclei rotate or pecesses known as Larmor Frequency (ω). Larmor frequency
depends on the gyromatric ratio (γ), ratio of angular momentum (J) and magnetic field (B0)
(Equation 1-2).

The following equation describes the angular momentum (J) and the magnetic moment where m
is the mass, v is the velocity and r is the radius of the proton.

𝑱 = 𝒎𝝎 = 𝒎𝒗𝒓

Equation 1-1

𝝎 = 𝜸𝑩𝟎

Equation 1-2

Subsequently, when a pulse of radiofrequency (Rf) electromagnetic radiation is applied
in the direction perpendicular to the magnetic field, the hydrogen nuclei absorbs this energy
causing it to perturb or to tilt from the magnetic field (Figure 1.3).Once the radiofrequency
pulse is removed, the nuclei in its high energy state decay back to the lower energy state, and
this process is called relaxation. The MRI measures the signal produced by the nuclei as it
relaxes or reorients back to its initial position relative to the magnetic field; from the aggregates
of these signals it generates an image. The time it takes for the nuclei to return to its original
orientation along the magnetic field corresponds to the enhancements in the MRI images. There
are two relaxation processes that occur simultaneously when the proton relaxes back to its
original orientation: longitudinal (spin-lattice) relaxation (r1) and transverse (spin-spin)
relaxation (r2)[20, 21]. The time it takes for the nuclei to realign back to its initial orientation in
the magnetic field along ZY plane is called spin-lattice or longitudinal time T1. As illustrated in
Figure 1.4A, during application of an RF pulse, the proton precesses with an angle of θ. Once
the RF pulse is removed, the proton resumes back to its low energy state (Z- axis) and the angle
9

θ decreases. This process is referred to as T1 relaxation time. Simultaneously, the nuclei spin dephasing along XY plane around the Z-axis. This dephasing process is called spin-spin relaxation
time T2 (Figure 1.4B).
One of major challenges of clinical MRI for human patients is its low sensitivity and
high background. Since most of human body is made of water, these relaxation rates of protons
associated with the tissue observed have minute differences with an enormous background
water signal. This leads to lower sensitivity in differentiating between the tissues of the interior
of two organs as compared to soft tissue. In order to make MRI suitable with increased
sensitivity for organ related diseases, contrast agents are widely used. However, there is a
pressing need to develop sensitivity MRI contrast agents to extend the clinical applications of
MRI. The objective of this thesis is to develop MR contrast agent with high relaxivity to enable
molecular imaging of biomarkers. In addition, we also improve their translational potentials by
reducing immunogenicity.
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Figure 1.3 Schematic representation of nuclei under magnetic field and their relaxation
process.
The nuclei in its original state have random orientation, when a magnetic field is applied
the spin states of these nuclei align parallel or anti parallel. When radiofrequency pulse is
applied, in the direction perpendicular to the magnetic field, the hydrogen nuclei absorbs
this energy causing it to perturb or tilting from the magnetic field. Once the
radiofrequency pulse is removed, the nuclei in its high energy state decay back to the
lower energy state along the Z-axis, and this process is called relaxation. There are two
relaxation processes that occur simultaneously when the proton relaxes back to its original
orientation: longitudinal (spin-lattice) relaxation (r1) and transverse (spin-spin) relaxation
(r2).
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A

B

Figure 1.4 Diagram depicting the process of (A) R1 relaxivity and (B) R2 relaxivity.
There are two relaxation processes that occur simultaneously when the proton relaxes
back to its original orientation: longitudinal (spin-lattice) relaxation (r1) and transverse
(spin-spin) relaxation (r2). The time it takes for the nuclei to realign back to its initial
orientation in the magnetic field along ZY plane is called spin lattice or longitudinal time
T1.during application of an RF pulse, the proton precesses with an angle of θ. Once the RF
pulse is removed, the proton resumes back to its low energy state (Z- axis) and the angle θ
decreases. This process is referred to as T1 relaxation time. Simultaneously, the nuclei spin
de-phasing along XY plane around the Z-axis. This de-phasing process is called spin-spin
relaxation time T2
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1.5. Contrast Agents in MRI
In order to attain MRI scans with sufficient sensitivity and enhancement, contrast agents
are often used. Around 30-50 % of clinical MRI scans are obtained by injecting MRI contrast
agents intravenously [22-24].Contrast agents enhance the signal corresponding to the relaxation
rate of water proton. Contrast agents can enhance the imaging signals along with distinguishing
the diseased organ from the regular ones. A typical MRI contrast agent shortens T1 and T2
relaxation time of surrounding water molecules and thereby enhances the contrast of the images.
This is described as relaxivities, r1 and r2.
Depending on their physical properties, MRI contrast agents have various categories.
“T1 weighted” contrast agents are capable of reducing both longitudinal (T1)and transverse
(T2) relaxation time of water hydrogen while“T2 weighted” contrast agents have shorter
transverse (T2) relaxation time as compared to longitudinal (T1) (Figure1.3 and 1.4). T1
weighted contrast agents brighten the image by producing positive contrast (gadolinium
complexes) whereas T2 weighted contrast agents darken the images by creating negative
contrast as with iron oxide contrast agents. The sensitivity and effectiveness of a contrast agent
rely on how well it can shorten the proton relaxation. These properties are achieved by using
paramagnetic, ferromagnetic or super paramagnetic metal ions containing unpaired electrons as
contrasting reagents. Gadolinium (Gd3+), a trivalent lanthanide metal ion with seven unpaired
electrons, high magnetic moments, long electronic relaxation times due to its symmetric s-state,
is the most frequently used metal ion. Gadolinium-based contrast agents are T1 weighted
because of its capability to shorten the longitudinal (T1) relaxation time. The interactions of
seven unpaired electrons of gadolinium with water protons generate a brighter contrast. The
direct coordination of water to the gadolinium center contributes to the inner sphere relaxation
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whereas the surrounding bulk solvent water contributes to the outer sphere relaxation. There are
many parameters that affect the relaxivity such as rotational correlation time, distance between
proton and center of gadolinium, water exchange rate with gadolinium (kexor1/ τm), the
electronic properties of the gadolinium ion (T1e) and hydration number of the inner and outer
sphere (q). Other parameters that may affect the relaxation process are the strength of the
magnetic field, and viscosity of the solution. Manipulating these parameters can help in the
development of better contrast agents as described in the following Equation 1-3 where 1/Tc1 is
the inverse Larmor frequency.

𝟏

𝑻𝒄𝟏

𝟏

𝟏

𝟏

=𝝉 +𝑻 +𝝉

𝑹𝟏,𝟐 =

𝑹

𝟏𝒆

Equation 1-3
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𝟏,𝟐
𝟏,𝟐

�𝑻

[𝑮𝒅𝟑+ ]

Equation 1-4

1.5.1. Current MRI Contrast Agents and their limitations
Free gadolinium is highly toxic by itself, for instance, the toxicity in mice is with an
LD50 of 0.2 mmol/kg. Thus free Gd3+must be coupled with a chelator that functions as a carrier
to encapsulate it in vivo. Current clinically approved contrast agents have one Gd3+ that is
incorporated into a small organic chelator such as diethylene triamine penta acetic acid
(DTPA),tetraazacyclododecane tetraacetic acid(DOTA) etc. (Figure 1.5)[25]. The primary
structures of these chelators vary from linear to cyclic structures. For instance, the
thermostability and dynamics of macro-cyclic ligand Gd-DOTA is relatively higher than that
linear of Gd-DTPA[22, 26]. These FDA-approved contrast agents have relaxivities of 4 – 5
mM-1 s-1, however; theoretically they are expected to have relaxivities of around 100 mM-1 s-1.
Due to slow water exchange and fast molecular rotation time (100 ps) of small chelators, the
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possibility of achieving such high theoretical relaxivity 100 mM-1s-1is significantly
compromised[22]. Along with this, they have short half-lives, so very high concentration (> 0.1
mM range), attained with repeated injection (at 0.1-0.3 mM/kg), is required in order to detect
changes in contrast caused by proton relaxation[6, 24, 27]. Such high concentrations of free
gadolinium, lower blood retention and decreased in vivo relaxivities may increase the risk of
causing nephrogenic systemic fibrosis (NSF), which affects the kidney. Studies have shown that
due to weak binding between Gd3+ and contrast agents leads to accumulation of free gadolinium
and free contrast agents in the kidney causes lack of proper excretion, and consequentially
causes renal failure.[28]There are certain restrictions imposed by the FDA in the dosage and
applications of these contrast agents, depending on the severity of the harm they may cause
shown in Figure 1.6. Moreover, these contrast agents have poor organ specificity and lack the
targeting capability. Thus, there is an urgent need to develop a contrast agent with high
relaxivity, higher rotational correlation time, better retention and potential targeting capability.
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Figure1.5 Commercially available, clinically used and FDA approved MRI contrast
agents. Adapted with permission from reference [25]
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Figure 1.6 List of contrast agents with certain restrictions and dosage approval worldwide.Adapted with permission from
reference[28]
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1.5.2. Criteria for designing Contrast Agents
As discussed above, in order to develop a clinically reliable protein-based MRI contrast
agent, it must fulfill certain criterion including high stability and solubility, appropriate
molecular weight, tolerance to mutations, high relaxivity, strong Gd3+ stability and metal
selectivity, no toxicity, and, last but not least, the production must be cost effective and time
efficient. In order to evaluate high quality contrast agent with less toxicity for clinical
applications, it must possess high in vivo relaxivity, that it must shorten the relaxation times (T1
and T2) to achieve maximum enhancement with a low dosage. A contrast agent must have
strong affinity and selectivity for the lanthanide metals (gadolinium) over other physiological
metals such as calcium, zinc and magnesium that can possibly compete with gadolinium and
release it out of the contrast agent causing toxicity and may hinder the outcome. It must also
have excellent in vivo stability without any interactions with proteolytic enzymes, proteins and
other physiological components that can cause degradation or cleavage, which can in return
increase blood retention time and minimize the dosage requirement. It must have the
appropriate size for fast circulation, renal filtration without any accumulation in the kidney.
Most importantly, it must have reduced immunological effects. Finally, molecular targeting of
diseased cells is highly desired to enhance the specificity of contrast agents to attain high spatial
resolution using MRI. Our lab has taken these factors into account and designed a suitable
protein-based contrast agent, and further optimized its properties by targeting it to cancer
biomarkers.
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1.6. Designing Protein-based MRI contrast agents – a novel approach
Yang Lab has developed a novel class of MRI contrast agents using proteins. A Gd3+
binding site was created on to a scaffold protein frame to increase relaxivity by controlling
correlation time, water in the coordination shell and addition contribution of the secondary shell
to relaxivity. The protein-based contrast agents, ProCAs were achieved based on our previous
studies on designing and engineering metal-binding sites in proteins and protein folding.
.Various computational and protein engineering strategies have been developed to introduce
metal binding pockets and alter the coordination without disrupting the protein folding and
compact tertiary structures. In addition, well-folded scaffold with appropriate size of about 2-3
nm (approximate molecular weight 10-12 kDa) have good tissue penetration, adequate
circulation time and are excreted through the kidney. Further, the recent development in
methodologies for determining structural and dynamic properties with sophisticated techniques
such as high resolution NMR have made it possible for designing MRI contrast agents with
desired metal (Gd3+) binding pocket and relaxation properties. Fifth, protein can be modified
and conjugated with moieties that can target diseased biomarkers.
Protein based contrast agent, ProCAs have several advantages over the commercial
contrast agents. Proteins engineering can generate a stronger coordination in the pre-existing
binding pocket to improve its metal-binding affinities and selectivity and can be used as
scaffold protein. When gadolinium binds to these altered scaffold proteins, they can probe in
increasing the amount of bulk water in the surroundings. The Gd3+ interacts with the
surrounding bulk water with one inner sphere water, three-second sphere water molecules and
several outer sphere water molecules (Figure 1.7A)[22]. With an optimal increase in molecular
size by conjugation of ProCA and with hydrophilic PEG reagents, the water exchange rate can
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be improved dramatically, which in turn increases the relaxivity. Conjugation with PEG
increases the tumbling or rotational correlation time τr, which is dependent on the molecular
size, and plays a major role in the enhancement of relaxation properties (Figure 1.7A). As
illustrated in Figure 1.7B, the simulations of magnetic field dependent relaxivities show that the
protein contrast agent has a rotational correlation time of 10 ns, which can increase the
relaxivities up to 10-20 folds by optimizing these parameters such as tumbling rate or rotational
correlation time, water exchange between inner and outer sphere of gadolinium. Newly
developed ProCAs that are well packed and have the optimal molecular size of about 10-12 kDa
and can be quickly excreted from the kidney. In addition, ProCAs can also be modified and
engineered with targeting moieties for various diseased biomarkers. Subsequently, our lab has
developed two generations of protein-based MRI contrast agents, with various targeting
capabilities that specifically target highly expressed biomarkers on cancerous cells.
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Figure 1.7 Schematic representation of the factors that can be optimized to improve the
properties of protein based contrast agent.
(A)When gadolinium binds to these altered scaffold proteins, they can probe in increasing
the amount of bulk water in the surroundings. Gd3+ interacts with the surrounding bulk
water with one inner sphere water, three-second sphere water molecules and several outer
sphere water molecules. Conjugation with hydrophilic PEG reagent with optimum
molecular weight increases the tumbling or rotational correlation time τr, which is
dependent on the molecular size, and plays a significant role in enhancement of relaxation
properties. (B) The simulations of magnetic field dependent relaxivities show that the
protein contrast agent has a rotational correlation time of 10 ns, which can increase the
relaxivities up to 10-20 folds by optimizing these parameters such as tumbling rate or
rotational correlation time, water exchange between inner and outer sphere of
gadolinium.Adapted with permission from reference[22]
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1.6.1. ProCA1
Previously, Dr. Jenny Yang’s lab has successfully overcome the above-mentioned
challenges and developed a series of novel classes of ProCAs. The first important step is the
selection of a scaffold protein that is tolerant to mutations and maintains its stability and rigid
structure when subjected to physiological environment [29]. In order to develop protein-based
contrast agents with high metal binding affinity, various proteins and small chelators were
studied for metal binding sites. Similar to Ca2+ and lanthanides such as Tb3+, and Eu3+, Gd3+ also
uses oxygen and nitrogen as ligand; however oxygen has higher preference as a ligand in a
protein molecule. Surveys for metal binding coordination of x-ray structures of calcium binding
proteins with calcium and lanthanide ions suggested that the average coordination number of
these lanthanide ions in an intrinsic protein EF-hand site was 7.2[30]. It is well known that these
lanthanides, Tb3+ and Eu3+ possess similar ionic radii and coordination number as Ca2+ and are
often used as fluorescent probes to determine Ca2+ binding affinities. In fact, many biological
functioning such as conversion of prothrombin to thrombin and activation of hemocyaninethat
are associated with calcium binding proteins can be efficiently performed by substitutingTb3+in
the system[31, 32].Hence, Calcium binding proteins can be an excellent candidate for the
selection of scaffold proteins. Proteins containing EF-hand motif as calcium-binding pockets
can form penta bipyramid structure with oxygen ligand and thus can be used as Gd3+ binding
pocket. EF-hand motif can be engineered in any desired scaffold protein to construct as a Gd3+
binding pocket. Previously, Dr. Yang’s lab introduced a de novo designed calcium-binding
pocket onto a non-calcium binding protein, domain 1 of rat CD2, which demonstrated selective
calcium binding over magnesium with dissociation constant of 50 μM that is very much similar
to naturally existing extracellular calcium-binding proteins[33, 34]. Domain 1 of rat CD2 is a
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derivation of cell adhesion 2 (CD2), originating from T-cell receptor in the immunoglobulin
response system. It maintains its original conformation a β-sheet topology, under varying pH
and temperature. [35]Initially, a calcium-binding pocket was constructed with five mutations to
test its binding capabilities and thermostability. This construct was further optimized to improve
its capabilities for strong binding with lanthanides such as Tb3+which showed a dissociation
constant less than 1 μM. [36, 37]. Modifying this calcium-binding site further, a novel design
approach has been introduced to engineer a gadolinium-binding pocket onto a stable protein,
domain 1 of rat CD2. For constructing the Gd3+ binding pocket, oxygen from the side chains of
Glu15, Glu 56, Asp 58, Asp 62, and Asp 64 was used as a ligand that comes together from the
different regions of the protein sequence and forms a binding pocket(Figure 1.8 A). In order to
allow fast water exchange rate between the metal ion and the solvent, one coordination position
is kept open. (Figure 1.8 A) After rigorous simulations and efforts, Domain 1 of rat CD2 was
optimized to have high relaxivity, r1 = 117 mM-1 s-1 compared to Gd-DTPA r1 = 5.4 mM-1 s-1
[22, 29] as ProCA1. The molecular size of ProCA1 is about 11 kDa, suitable for optimal
rotational rate and longer blood retention with easy renal excretion. As mentioned earlier,
ProCA1 is conjugated with 12 kDa PEG to further improve its in vivo properties as contrast
agent and enhancement has been achieved (Figure 1.8 B)[22, 38]. Previous lab members have
successfully targeted ProCA1 by introducing various moieties that can target HER-2 receptor on
breast cancer cells[6] and GRPR receptors on prostate cancer biomarkers.(unpublished data)
Senior lab member, Dr. Qiao has successfully developed targeted ProCA1 by
incorporating into an affibody that can target to these overexpressed HER2 receptors on breast
cancer cells. Affibody (7 kDa) is obtained from the Z- domain of Protein A, and acts as an
antibody that targets these receptors on cell surface. Affibody was grafted onto the C-terminal
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of ProCA1 with a flexible linker, GGSGG that prevents steric hindrance between two moieties.
Two variants were constructed to target EGFR and HER2 receptors; both demonstrated high
relaxivities, sensitivity and excellent targeting capabilities as compared to the commercial
contrast agents[6]
As shown in Figure 1.9, GRPR are known to have high expression on prostate cancer
cells [27]. In order to develop molecular imaging probe to target prostate cancer, ProCA1 has
also been linked with various analogs of GRP peptides via similar grafting approach to target
against GRP receptors as discusses in section 1.3

A

24

B

C

Figure 1.8 Model structure of ProCA1 with binding gadolinium binding pocket and its coordination.(Generated by Chimera UCSF).
(B) Oxygen ligands from the side chain of Glu15, Glu56, Asp 58, Asp62 and Asp64 are
used at different stretches of the protein sequence of domain 1 of CD2 (pdb:1hng). One
position of metal geometry is left open to allow fast water exchange between solvent and
metal. (C) MRI scans of mice organ enhanced (b) 20 minutes, (c) 3 hours, (d) 24 hours
after the injection of ProCA1 compared with (a) prescan, (e) the intensities of kidney and
liver before and after injection of ProCA1. (B) and (C) Adapted with permission from
reference[38]
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1.6.2. Grafting approach on ProCA1 for targeting GRPR
As discussed in Section 1.3 and Figure 1.9, gastrin-releasing peptide (GRP) is a natural
ligand that can target these overly expressed GRPR on the tumor cells in the prostate. GRP is a
peptide that is twenty-seven residues long and belongs to the family of bombesin like
peptides[1]. Bombesin is a fourteen amino acid long peptide, which was originally isolated from
a frog’s skin. GRP -27 is similar to bombesin-14, which has conserved C-terminus (Figure
1.9).The conserved region presumably be playing an important role. Both peptides have high
binding affinity (and the targeting ability) to GRPR expressed on prostate tumor surface.
Various analogs of GRP and bombesin peptides have been studied: bombesin-14 has stronger
binding affinity for GRPR followed by GRP1-27(Figure 1.9). Thus, gastrin-releasing peptide and
bombesin can be used to study, monitor and target prostate cancer.
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Figure 1.9 The sequence alignment of conserved residues at C-terminal of GRP and
Bombesin. Binding affinities of ligands targeting GRPR. Adapted with permission from
reference[1]

Previously, a 10 amino acid peptide chain from the C-terminus of GRP (GRP1-10) has
been inserted into ProCA1 sequence by two ways: by conjugating the peptide at C-terminal of
ProCA1 (ProCA1.GRPC) and by grafting the GRP peptide between Glycine52 and Glycine53
in the PRoCA1 sequence (ProCA1.GRP52) (Figure 1.10) (designed by PhD student Lexia
Wei)[27]. Although, both targeted variants demonstrated high relaxivities; ProCA1.GRP (52)
has a significantly stronger binding affinity for GRPR receptor on prostate cancer cell lines
[27]. These results suggest that grafting a small peptide into ProCA1 does not affect its
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properties as a contrast agent and indeed does not disrupt its original confirmations and folding.
Now that it is established that grafting approach demonstrates better targeting abilities,
remaining analogs of GRP and bombesin could be examined for targeting GRPR. In order to
further optimize and improve the in vivo molecular targeting of ProCA1.GRP 52, ProCA1
conjugated with ten amino acid peptide of GRP to GRPR on prostate cancer, Dr. Fan Pu has
developed two more variants keeping the targeting ability of bombesin14. Further in the thesis
ProCA1.GRP52 is referred to as ProCA1.G10 (or GRP1-10). Hypothetically, the conserved
region of 10 amino acids in bombesin-14 (bomb1-10) can have similar targeting capability as
GRP1-10 (G10) peptide. To test this hypothesis, two peptides bombesin1-10 with 10 conserved
residues (B10) and bombesin-14 (B14), the entire peptide chain were grafted between Gly52
and Gly53 via the GGSGG flexible linker referred as ProCA1.B10 and ProCA1.B14
respectively (Figure 1.11)

Figure1.10 Two approached: engineering of targeting sequence via (left) inserting it at Cterminal of ProCA1 (ProCA1.GRPC) and (Right) grafting into the ProCA1 sequence
between Gly52 and Gly53 (ProCA1.GRP (52)). Adapted with permission from reference
[27]
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Figure 1.11 Model structure of ProCA1 grafted with G10, B10 and B14 using flexible
linker GGSGG (obtained by ITASSER)(Shenghui Xue’s dissertation)[39]

1.6.3. ProCA32

As discussed earlier, Dr. Jenny Yang’s lab has developed a series of novel protein-based
MRI contrast agents with engineered Gd3+ binding sites into a scaffold protein CD2. The first
generation of ProCAs, demonstrated improved relaxivity, sensitivity, selectivity, stability and
high targeting capability as compared to the commercially available contrast agents. Although
ProCA1 demonstrated excellent r1 and r2 relaxivities it exhibited relatively weaker Gd3+ binding
constants than the dissociation constant of the commercial contrast agent Gd-DTPA (1.86 × 10 21

M), which is extremely important for in vivo application as an MRI contrast agent to further.

So to improvise the stability by selecting a thermodynamically stable scaffold proteins and
metal binding by additional binding sites to increase the payload, a series of the third generation
of ProCAs, ProCA3 were designed by Dr. Shenghui Xue. A new scaffold protein, rat α
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parvalbumin(PV) was selected due to many advantages associated with its physical and
functional properties. Firstly, parvalbumin is a small rigid and globular protein with a molecular
weight of 11-12 kDa Parvalbumin. PV is a part of calcium-binding protein family, consisting of
two Ca2+ binding sites, and naturally functions as a cytosolic Ca2+ buffer [40].As discussed
earlier, EF- hand motif can form a pentagonal bipyramid structure using oxygen as a ligand and
can be an excellent tool for gadolinium binding. Furthermore, Henzlet.al has shown that the
calcium binding affinity of parvalbumin can be altered by performing mutations of the key
residues in these two binding sites and can be as low as 10-9 M.[41-43]The presence of two
metal binding sites (AB and CD sites) gives an advantage for designing a potential ProCA with
more payload. Although lanthanides possess higher charge, due to similarities in the
coordination numbers and with ionic radii almost similar to calcium’s lanthanides have a high
affinity for Ca2+ sites on biological molecules and stronger interactions with surrounding water
molecules.[44]Interaction with surrounding water molecules is significantly important for
optimizing the relaxation property of a contrast agent. Most importantly parvalbumin has a
strong thermostability, high solubility, and resistance to protease cleavage and is tolerant to
mutations. Keeping the above parameters in mind, different mutants of ProCA3, with PV as
scaffold protein, were generated to engineer a stronger Gd3+ binding site.
Wild-type parvalbumin has two calcium binding sites that are EF-hands. EF-hand site 1
(CD) is formed by four carboxyl ligands (D52, D54, E50, and E63) and one non-charged
oxygen ligand (S56) that directly interact with Ca2+. EF-hand site II (EF) has carboxyl groups
(D91, D93, D95, and E102) and uses G99 was water ligand to hold Ca2+ in the binding pocket.
As mentioned earlier, calcium and lanthanide ion binding affinities can be selectively improved
by introducing a negative charge in the binding pocket. Various mutations were performed and

30

tested for its metal binding and relaxivity.ProCA32, one of the engineered contrast agents that
contain two EF hand binding sites located in helices EF and CD and one additional EF-hand
motif AB, with one site mutation within the CD binding pocket (S56D). An increased metal
selectivity for Ca2+ or lanthanides can be achieved by increasing the negative charge in the
metal coordination shell[44]Hence, negatively charged ligand with S56D mutation in the CD
motif was performed to increase the Gd3+ binding affinity. Furthermore, an additional mutation
(F103W), adjacent to the CD binding pocket, was made to enable fluorescence emission
analysis. ProCA32 demonstrated stable serum stability, has low toxicity and behaves as a
ratiometric T1/T2 weighted contrast agent. The interaction with gadolinium and other metals
were tested through a series of biophysical applications described in Dr. Shenghui Xue’s
dissertation (Figure 1.12). In order to consider ProCA32 as a suitable protein drug for the
diagnostic and therapeutic of the human disease, it must fulfill certain requirements. There are
several factors to be considered for the proper activity of the protein drugs in vivo. Based on
these studies, the next step would be to develop a humanized ProCA32 with similar mutations.
As shown in the Figure1.13, there are nine residue differences between the wild type rat PV
and wild type human PV. Among these nine residues, only one residue, Asp located in the
binding pocket, EF-hand site II (highlighted in cyan) was mutated to Glu (D101E) to make
similar binding pocket as ProCA32. The remaining two mutations, S56D located in the binding
CD binding site and F103W (highlighted in red) were performed to further achieve similar
metal binding and relaxation as compared to rat ProCA32 (Figure1.13).
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Figure 1.12 A Cartoon model of rat ProCA32 and MRI images.
(A) Model structure of ProCA32 using Chimera UCSF sequence derived from x-ray
crystal structure.[45](B) The MRI image of mice before and 50 minutes after injection of
ProCA32 (unpublished data) [39] the contrast agent clearly enhances the liver and blood
vessels as it is being distributed out from liver via blood.
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Figure1.13 Protein sequence alignement of hCA32 with rat ProCA32, wild type rat
Parvalbumin (ProCA30) , wild type human parvalbumin (hCA30).
(Top right) Model structure of wild type human CA32 using Chimera UCSF sequence
derived from x-ray crystal structure, 1RK9[46]. (Top left) Two Gd3+binding pockets were
generated on the CD and EF-loop of helix-loop-helix structure in wild type human PV by
mutations at (CD site I) S56D and D101E (EF site II). Orange dot is for Gd3+ metal in the
center, purple dots surrounding the metal ion correspond to the charged oxygen ligand for
Gd3+from carboxyl group, black dot indicates the oxygen ligand for Gd3+from protein
main chain and blue dot in site II is for the oxygen ligand from the surrounding water
molecule.(Bottom) the Protein sequence alignment of the wild type rat and human PV
with rat ProCA32 and hProCA32. The ones highlighted in yellow are the amino acid
difference between rat and human PV. The ones highlighted in red indicate the key
mutation in rat and human ProCA32 (1) to improve metal binding affinity (S56D) and 2)
for studying the fluorescence assay (F103W).
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Figure 1.14 Overlay of hCA32 and rat ProCA32 using UCSF Chimera
Structure in yellow is rat ProCA32, 1rwy with mutation S56D and F103W performed
using chimera UCSF[45] and purple is hProCA32, 1RK9 with mutation S56d, E101D and
F103W using chimera UCSF [46].
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1.7. Additional challenges in developing a Protein Based MRI Contrast Agents for
clinical applications
In developing a novel class of contrast agent that can be utilized in clinical applications,
there are several hurdles that need to be crossed. Primarily, the production of these newly
engineered contrast agents must be optimized to get well-folded, stable and high yield of
ProCAs for further in vivo studies. Purification protocol that can be easily applied into large
scale or industrial setting must be optimized for ProCA1 variants and humanized ProCA32
(hCA32). To further move into the next phase of pre-clinical trials of therapeutic and diagnostic
drug discovery, the contrast agent must in be used for larger animal followed by clinical trials.
When non-human analogs of drugs are used, they tend to initiate immune response.

1.7.1. Approaches to reduce Immunogenicity
The main aim of developing these new generations of protein based contrast agents is to
address the clinical relevance by reducing its immunogenicity. Immunogenicity of the protein
therapeutics remains one of the most challenging aspects in the field of drug discovery and
therapeutics industries. Many of these non-human protein sequences like fusion proteins,
engineered protein variants that are derived via bacterial medium and other monoclonal
antibodies can possess higher clinical performances, novel functions and have potency to
become pioneers of drug therapeutics, however, due to the major barrier caused by
immunogenicity such remarkable preliminary discoveries remains futile[47].When these
exogenous therapeutic protein drugs are introduced into the human body, the immune system
tends to form antibodies against it.

Thus, the most essential requirement to address the

immunogenicity is to reduce the immunogenicity along with maintaining the desired structural
and functional significance. There are various means to address immunogenicity including
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modification by PEGylation, site-specific mutagenesis, exon shuffling or humanization[48].
Recently, a new method has been developed to target immunogenicity here the therapeutic drug
is modified with sugar, glycosylation [49].
Humanization of desired non-human protein will essentially increase its survival into
immune system and reduce the immunogenicity response. Along with reduced immunogenicity,
to allow protein therapeutics for successful application it is necessary to optimize and consider
several factors such as solubility, stability, pharmacokinetics, and pharmacodynamics it must
also have optimized pharmacokinetics, low cost and reproducibility for industrial production.
An alternate approach to reduce immunogenicity is to modify it with long polyethylene glycol
(PEG) chain that can sterically block the antibodies by masking the protein drug without
interfering with its therapeutic applications. PEGylation not only reduces immunogenicity but
also solubilize the protein drug by preventing aggregation. Due to the increase in the molecular
size, PEGylation can also increase the half-life of the drug enhancing its stability [49, 50].
Hence humanization of our contrast agent and conjugating it with PEG can help us reduce the
immunogenicity effects our
1.8. Objective of this Thesis

Initially in this work, previously established first generation of protein-based MRI
contrast agent (ProCA1) (designed by senior members Dr. Lixia Wei and Dr. Fan Pu) has been
expressed and purified to achieve high yield of ProCA for in vivo GRPR targeting studies. The
primary goal of this study is to optimize the production of a humanized third generation of
protein-based contrast agent, hProCA32 and to characterize it’s in vitro biophysical properties
as a contrast agent. The primary objective is to understand the key determinants of metal
binding properties and selectivity over physiological metals. Similarities between rat and human
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α-parvalbumin, due to the conserved EF-hand motif, suggests that the functional similarities and
relevance of both proteins. hProCA32 can be expected to have similar in vitro and in vivo
properties as ProCA32 as an MRI contrast agent. The initial goal is to optimize the expression
and purification process using the bacterial system to isolate the pure form of hCA32 with
relatively high yield. The secondary goal is to characterize the biophysical and functional
properties using fluorescence metal titrations and binding studies. Eventually improve the in
vivo properties such as stability, solubility, and relaxivity and reduce immunogenicity and
toxicity by modifying hCA32 with various lengths of polyethylene glycol chains (PEGylation).
The overall goal is to develop a novel class of protein-based contrast agent with reduced
immunogenicity that has similar functional, physiological and contrasting properties as
ProCA32.
In Chapter 1 discusses the general background and development of Protein based MRI
contrast agent. In Chapter 2, methodologies and experimental details that are implemented for
development ProCAs has been described. The bacterial expression, tagless purification and
relaxivity measurements of first generation of ProCA and its targeted variants against prostate
cancer have been performed in Chapter 3. In Chapter 4, E. coli bacterial expression of hCA32 in
various competent cells and its purification will be shown. Furthermore, 15N labeling of hCA32
via E.coli expression and purification has been optimized for future metal binding affinity-using
NMR studies (Chapter 4). The site directed mutagenesis of hCA32.cys and its bacterial
expression and purification is shown in Chapter 4. Lastly, the structural characterization of
hcA32 and its biophysical properties such as relaxivity, binding affinities for terbium,
gadolinium, calcium, and zinc, metal selectivity is shown in chapter 5. Site-specific cysteine
PEGylation of hCA32 with various lengths of PEG, its stability in human serum and the
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enhancing capability of hCA32 has contrast agent is also shown in Chapter 5. Chapter 6
describes the significance of this work and its future applications in the field of MRI imaging
and possible targeting against cancer biomarker. The protein-based MRI contrast agents
discussed in this thesis are described in Table 1.2.

Table 1.2 Summary of all the ProCAs described in this thesis.
1

Designed
Description
Mutations
contrast agents
First generation of ProCA
with domain one of rat
ProCA1
CD2 as scaffold protein
N15E, L58D, K64D
with one Gd3+ binding site
ProCA1 grafted with 10
Grafted peptide:
ProCA1.G10 amino acid peptide
GNHWAVGHLM
obtained from GRP
ProCA1 grafted with 10
Grafted peptide:
amino acid peptide
ProCA1.B10
GNQWAVGHLM
obtained from bombesin
ProCA1 grafted with full
length peptide (14 amino
Grafted peptide:
ProCA1.B14
acid) obtained from
EQRLGNQWAVGHLM
bombesin
The third generation of
ProCA with two Gd3+
ProCA32
binding sites in a scaffold
S56D, F103W
protein, rat Parvalbumin
Humanization of third
generation of ProCA with
two Gd3+ binding sites in a
S56D, D101E, F103W
hProCA32
scaffold protein, human
Parvalbumin
hProCA32 with additional
cysteine at the C-terminal
Inserted Cys residue at
hProCA32.Cys
for site specific PEGylation
C- terminal
and labeling.

1

Molecular
weight
11.146 kDa

12.824 kDa

12.814 kDa

13.341 kDa

11.992 kDa

12.140 kDa

12.243 kDa

ProCA1 variants were designed by Dr. Lexia Wei and Dr. Fan Pu. rProCA32 and hProCA32
were designed by Dr. Shenghui Xue.
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2. MATERIALS AND METHODS
2.1. Expression of ProCA1 and its variant
2.1.1. Cloning

Figure 2.1pET-20b(+) vector for ProCA1 variants overexpression.
The DNA sequence of ProCA1 (7E15) was cloned by senior lab member Dr. Anna
Wilkins Manicia in accordance with the protocol described in her PhD dissertation.
A gadolinium binding pocket was constructed by performing several mutations on a stable
scaffold protein, domain 1 of rat CD2. ProCA1.GRP10 (ProCA1.G10) was cloned by inserting
codons for 10 amino acid residues from the C-terminal of GRP linked to a flexible linker
GGSSGG (Dr. LixiaWei). The DNA sequences of ProCA1.bombesion10 (ProCA1.B10),
ProCA1.bombesin14 (ProCA1.B14) and ProCA1.PSMA were cloned by senior PhD student
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Fan Pu. All these cloned DNA sequences were inserted in to ampicillin resistant pET-20b
vector by PCR.
2.1.2. Transformation
Transformation is a commonly used technique to introduce genetic alterations into a host
cell through the uptake of foreign DNA. E. Coli strains, BL21 (DE3) was used for
transformation and left on ice to thaw for about 10 minutes. Simultaneously, plasmids for
ProCA1, ProCA1.G10, ProCA1.B10, ProCA1.B14 and ProCA1.PSMA were also placed on the
ice to thaw. A volume of 1uL of plasmid was mixed with 40 μL of thawed BL21 (DE3)
competent cells and place on ice for about 60 minutes. This was done is a sterile environment to
avoid any possible contamination. The mixture was then incubated in a heat bath at 42 ℃for
exactly 90 seconds and then quickly placed on ice for two minutes. Performing this heat shock
method is very crucial on the membrane of the E. coli cell strains. A sudden increase in the
temperature causes the competent cell to be vulnerable by creating pores on its cell membrane
allowing the recombinant DNA to penetrate into the bacterial cells. Approximately 90-100 uL
of freshly autoclaved LB medium was added and was further left in an incubator (Fisher
Scientific) at 37 °C for 30 minutes. The mixture was then streaked on an agarose/LB ampcilin
plate with L-shaped loop and stored in an incubator at 37 °C overnight. The plates were placed
upside down for better growth. The following morning each plate was observed for the presence
of healthy bacterial colonies. An E.coli bacteria competent cell strain of BL21(DE3) was
transformed with the desired plasmids containing pET-20b vector. These plates were covered
with parafilm and conserved at 4 °C. This transformation protocol is summarized as a scheme in
Figure 2.2
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2.1.3. Inoculation
In order to effectively express the desired protein, it must be initially
overexpressed in a small volume of Luria Bertani (LB) culture medium overnight. A 250 ml
flask containing 100 ml LB medium for inoculation was autoclaved at extremely high
temperature. A healthy colony from the freshly transformed plate was selected and inoculated in
a 250 ml flask of Luria Bertani (LB) medium with 100 mg/L ampicillin. This process was
performed under sterile environment to minimize any possible contamination. The inoculated
medium was then incubated in a shaker at 37 °C at 230 rpm overnight. The next day, each
inoculated flasks were observed for cloudy solution indicating bacterial growth. Using a Uv-Vis
Spectrophotometer (Shimadzu UV-Visible), optical density of the inoculated sample was
recorded at a fixed wavelength of 600 nm with a final OD600 close to 2. These cells were further
used to for large-scale expression using E. coli cellular system.
2.1.4. Expression
A 50 ml volume of overexpressed culture was transferred to one-liter pre-autoclaved
LB medium in two-liter flasks containing 100 μg/mL of ampicillin. These flasks were incubated
in a shaker at 37°C at 220 rpm. Simultaneously, the rapidly growing bacterial cells were
supervised by measuring optical density (OD600) using a Uv-Visible spectrophotometer (UV1601, Shimadzu Scientific). Isopropyl β-D-1-thiogalactopyranoside (IPTG) with final
concentration of 200 μM was used to induce the growing bacterial culture, when the optical
density reached (OD600) reached 0.6-0.8. The protein was continuously expressed at 25°C
overnight after the induction with IPTG. The cultured medium was than centrifuged at 7000
rpm for about 30 minutes at 4 °C. Cell pellets were collected and stored at -20 °C. samples were
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collected at various time points before and after IPTG induction to confirm the expression of the
protein using gel electrophoresis.

Figure 2.2Summary of Transformation (top) and Expression procedure (Bottom
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2.2. Tagless purification of ProCA1 and its variants
2.2.1. Sonication and cell disruptor
Cell pellet obtained after centrifugation was re-suspended in 20 to 40 ml of
homogenization buffer (1X Phosphate-buffered Saline with pH adjusted to 7.4 with HCl). The
mixture was mixed with 1.0 uL benzonuclease and 200 uM Phenylmethylsulfonyl-Fluoride,
PMSF). Benzonuclease- MgCl2 is an endonuclease a typical restriction enzyme that cleaves the
phosphodiester bonds in a polynucleotide chain and eliminates DNA-RNA form the cell lysate.
PMSF is a protease inhibitor that prevents the desired protein from being cleaved by a variety of
proteases in the solution and aids in maintaining the purity and yield of the protein. In order to
homogenize the mixture, the solution was then mixed well using a vortex. The resulting solution
was subjected to sonication 5 times for 30 seconds with 5 minutes interval between each
sonication, in order to avoid protein degradation due to heat generated by sound waves of
sonicator. The purpose of using sonicator was to break all the bacterial cell membrane by sound
waves. The mixture was further homogenized by using a cell disruptor. Like sonicator, cell
disruptor is to break the cell membrane and other cellular components from the protein. The
mixture was than centrifuged at 17000 rpm for 30 minutes and the supernatant was discarded.
Under these conditions, most of the desired protein is contained in insoluble inclusion
bodiesand the unwanted soluble cellular components were eliminated in the supernatant. The
desired protein obtained in the form of pellets were then re-suspended in 2 % Triton, a mild
detergent, to wash out unwanted cell debris such as lipid impurities in the form of supernatant.
Cell pellets were washed three to four times with 2 % Triton X-100 at 4 °C for about 30 minutes
and centrifuged (13000 rpm at 4 °C) between each wash for 30 minutes. After each wash, cell
pellets turned white and the supernatant was discarded. Further, the collected cell pellet was
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dissolved in 25 ml of 8 M urea prepared in PBS and stirred overnight at 4 °C to completely
solubilize the cell pellet. Protein denaturants like 8M urea are quite often used with a purpose of
solubilizing the protein subsequently a complete unfolding of the protein, which can then be
gradually refolded back. The solubilized protein present in 8M urea solution was centrifuged
and supernatant was collected. The obtained supernatant containing soluble and completely
unfolded protein was then allowed to gradually refold back by decreasing the Urea
concentrations. This was done by dialysis in 4 M urea (overnight) in PBS, followed by 2M urea
for 4 hours in PBS. Next, the protein was dialyzed in10 mM HEPES with pH adjusted to 8.0
with HCl. The buffer was changed after 1 hour, and again after 4 hours, and then allowed to
equilibrate overnight. The dialysis was manipulated at 4 °C to prevent the protein from
degrading. The obtained sample was then further purified by FPLC using anion exchange
column.
2.2.2. Purification by FPLC: anion exchange HiTrap Q Column

Fast Protein Liquid Chromatography (Äkta-FPLC, General Electric, #INV-907, made in
Sweden) is a chromatographic process in which the protein solution is exposed to a salt gradient
(Q-column, Hi-trap Q-HP5 ml, GE Health care) program. Two buffers were prepared: Buffer A
(10 mM HEPES adjusted pH to 8.0 with NaOH) and Buffer B (10 mM HEPES, 1.0 M NaCl at
pH 8.0). Buffer A was filtered to remove particles and pH was adjusted. The sample loops were
connected with the machine. The anion exchange, Q column and the sample loops were washed
using ddH2O. The Q column and loops were than washed by high salt concentration solution,
Buffer B, followed by no salt solution, Buffer A. This was done at flow rate of 5 ml/min, alarm
pressure at 5 mPa, for 5 min with no existence of bubbles. A little protein sample was injected
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into the sample loops to discharge any air out of the system. Once this was done the entire
remaining protein sample was injected in to the loop. When the entire sample eluted out into
different fractions, they were separated based on the peaks and conserved at -20 °C. The system
was washed with high salt concentration buffer and ddH2O to remove any remaining protein
from the system. SDS gel electrophoresis and UV spectroscopy (Shimadzu) were used to check
the presence of target protein. The detailed procedure for determining protein concentrations
using UV spectrophotometer is described in Section 2.7. UV absorbance at 280nm was
monitored to identify the protein from eluted samples, which included protein and DNA. Due to
the presence of tryptophan and tyrosine residues, the protein exhibits high absorbance at 280 nm
and the nucleotides in DNA strongly absorbs at 260 nm. These results could be rechecked with
the SDS gel electrophoresis by comparing the brightness of the protein band at the expected
molecular weight of about 12 kDa.
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Figure 2.3Summary of Purification Process for ProCA1 and its variants.
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2.3. Expression of humanized ProCA32 (hProCA32)

Figure 2.4 Map of pET-22b(+) vector for hCA32 variants overexpression.
The DNA sequence of hCA32 was cloned into pET-22b (+) by Dr. Shenghui Xue and
the procedure can be obtained from Dr. Shenghui Xue’s dissertation[39].The gene encoding for
human alpha parvalbumin with two mutations, one site mutation in the EF hand binding pocket
and tryptophan residue close to the binding pocket, were inserted into the pET-22b(+) vector
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between the NdeIandXho I restriction enzyme sites. Plasmid transformation was performed on
pET-22b (+) hCA32 in BL21 (DE3).pLysS and BL21(DE3) cell strains, following the
procedure in section 2.1.2. One round colony was selected from a previously transformed plate
and inoculated into 200 ml of freshly prepared, and autoclaved LB medium containing 100
ug/mL of ampicilin. The protein was further expressed using the expression procedure
mentioned in section 2.1.4
2.3.1. Expression of 15N Labeled hCA32
Plasmid transformation was performed on pET-22b (+) hCA32 in BL21 (DE3).pLysS cell strain
following the procedure in Section 2.1.2. One round colony was selected from previously
transformed plate and inoculated in 200 ml of freshly prepared M9 medium containing 0.6 g
Na2HPO4, 0.3g KH2PO4, 0.15 mg FeSO4, 0.02407 g MgSO4, 0.11 mg CaCl2, 1.0 mL
micronutrients, 50mg NaCl, 0.05 mg thiamine, 0.2 g of glucose and 1.0 mL of vitamin
supplements and 0.5 g/L of

14

NH4Cl along with 200 uL of ampicilin.

15

N labeled

15

NH4Cl is

expensive so the initial small-scale overexpression in 200 mL was done using the 14NH4Cl. The
inoculated flask was left in shaker at 37 °C overnight. The 15N labeled hCa32 was expressed in
M9 medium, which contains 6 g Na2HPO4, 3g KH2PO4, 0.0015 g FeSO4, 0.2407 g MgSO4,
0.0011 g CaCl2, 1.0 mL micronutrients, 0.5 g NaCl, 5 mg thiamine,2 g of glucose and 10 mL of
vitamin supplements. 0.5 g/L of

15

NH4Cl were added as the source for the isotopic nitrogen.

One Liter of medium was divided into two 500 mL volumes to get improved yield. Two flasks
were left in shaker at 37 °C and OD absorbance were measured during the expression process.
Once the OD value reached 0.6, 200 µM of IPTG was added for the induction and the cell pellet
was collected after 4-5 hours after induction.
purification method mentioned in Section 2.4
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The protein was purified using the same

2.4. Tagless Purification of humanized ProCA32 (hProCA32)
2.4.1. Sonication and Boiling
In order to obtain protein from the over expressed in E.coli cultured medium, the
bacterial cells were broken using sonication via application of high energy sound wave to
disrupt the phospholipid bilayer and release out the cellular components. For this purpose, the
cell pellet obtained from the expression of hCA32 was solubilized in 30 mL in 10 mM HEPES
buffer, pH 7.3 along with 1uL of benzonuclease and 1mM PMSF. The mixture was vortexed to
generate a homogenous solution. The mixture was then sonicated 10 times with each cycle
lasting for 2 minutes. The sonicated solution was further centrifuged at 13000 rpm to collect the
supernatant. Collected supernatant was heated at 80-90 °C for about 15 minutes and centrifuged
at 13000 rpm. hProCA32 is stable at extreme temperature thus heating will denature unwanted
proteins.
2.4.2. Nucleic Acid Precipitation
The DNA and RNA contamination among tagless purification procedure is a common
phenomenon and can be resolved using endonucleases. However, the use of benzonuclease
alone does not efficiently remove the DNA and RNA when purifying ProCA3 variants.
Therefore, in an effort to optimize the purification protocol for all ProCA3 variants, previous
lab member, Dr. Shenghui Xue, conducted a series of experiments using streptomycin-sulfate to
eliminate nucleic acids from the solution. Streptomycin-sulfate is an antibiotic agent that binds
to the DNA/RNA and precipitate then out of the solution. In order to precipitate out DNA and
RNA, 3 % of a 30 % streptomycin-sulfate solution was added to the supernatant and left at 4°C
overnight. The resulting mixture was centrifuged and supernatant was again heated at 80-90 °C
for about 10 minutes and centrifuged at 13000 rpm. The collected supernatant was dialyzed in
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10 mM HEPES pH 8.0 at 4°C overnight. The sample obtained from dialysis was centrifuged to
remove any possible precipitates formed. The protein was dialyzed in presence of chelax-100
chelating resin to remove as much ions as possible from the protein solution. The supernatant
was then passed through FPLC anion exchange Q column to remove DNA/ RNA, and other
impurities following the protocol mentioned in section 2.2.2.

2.5. Molecular Cloning
2.5.1. Site directed Mutagenesis for humanized ProCA32.Cys
In order to insert a cysteine residue at C-terminus of hCA32, a general procedure for
site- directed mutagenesis was performed. A cysteine residue was inserted into the plasmid by
forward and reverse primer using polymerase chain reaction (PCR). Both forward and reverse
primers were phosphorylated prior to the experiment. Annealing temperature is the key factor
for successful PCR. Thus keeping the length of the primers and the template DNA in mind, Tm
was kept at 65 ° C for the total time of 6 minutes. The PCR product was obtained and digest
with Dpn1 restriction enzyme and incubated at 37° C for about 2 hours and kept at 4° C
overnight. Further the product was transformed using XL10 gold competent cells and grown on
LB/ampicillin plate. XL10 gold competent cells are often used for amplification for cloning and
ligated plasmid to obtain high transformation efficiencies. About eight round and healthy
colonies were selected for inoculation into 10 ml of LB medium and left on shaker at 37° C
overnight. The DNA was extracted using the general amplification protocol. The amplified
plasmid was then digested using Xho I cleavage site to cut open the circular plasmid for further
analysis using an agarose gel electrophoresis. The correct plasmid constructs were confirmed by
DNA sequencing.

50

2.5.2. Plasmid reconstruction of pRSET-CD20
2.6. Expression and purification of hCa32.cys
Plasmid transformation was performed on pET-22b(+) hCA32.cys in BL21(DE3).pLysS
E.coli cell strain following the procedure in 2.1.2. One round colony was selected from
previously transformed plate and inoculated in 200 ml of freshly prepared and autoclaved LB
medium along with 200 uL of ampicilin. The Protein was further expressed using the expression
procedure mentioned in section 2.1.4 and purified using the protocol mentioned in section 2.3
2.7. Concentration Determination using Ultraviolet-visible absorbance spectra
The concentrations of purified protein solutions were determined using a UV-VIS
spectrophotometer by monitoring UV absorbance ranging from 350-219 nm (UV- probe version
2, Pharma spec. 1700, Shimadzu scientific Instrumentation Inc. Newton, CT).Quantitatively, the
UV-VIS absorbances were recorded for each concentrated protein solution, in order to
experimentally determine the final protein concentration (C). Two quartz cells with a length of
1 cm containing 800 μL of nanopure water (ddH2O) was scanned from 350-219 nm to create a
baseline in order to subtract the absorbance differences. One of the quartz cells was replaced
with a cell containing protein solution and measured from 350-219 nm. The detection limits for
UV absorbance ranges from 0.1 to 1.0. Hence, the protein solutions were diluted if their
absorbances exceeded 1.0. The absorbance maximum value at 280 nm displayed in the
spectrum was multiplied by the dilution factor to obtain C in the Equation 2.1.The molar
absorptivity (ε) of wild-type CD2.domain1 was experimentally determined by previous lab
members, based on the presence of tryptophan, tyrosine and disulfide bonds[51]. The theoretical
value obtained based on primary amino acid sequence using online database Protein calculator.
(Available at http://www.basic.northwestern.edu/biotools/proteincalc.html).The experimental
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molar absorptivity of ProCA1 is 11740 M-1cm-1 where as the theoretical molar absorptivity
estimated by protein calculator, 13940 M-1cm-1. The theoretical extinction coefficients of
ProCA1 variants (ProCA1.G10, ProCA1.B14 and ProCA1.B10) are 19630 M-1cm-1.
The theoretical molar absorptivity of hCA32 variants determined using online data base
protein calculator was 5690 M-1cm-1.The experimental molar absorptivity value was used in the
Beer Lambert equation for obtaining CF

𝑨 = 𝜺 𝒃𝑪

Equation 2-1

2.8. Western Blotting
Gel electrophoresis with15% percent SDS gel was used to run the protein samples.
The electrophoresed gel was placed in a Blot Module with the nitrocellulose transfer membrane.
The electrophoresed gel and membrane are sandwiched between sponge and filter paper and all
are clamped tightly together after ensuring no air bubbles are trapped between the gel and
membrane. The negatively charged proteins in the electrophoresed gel are transferred onto the
nitrocellulose membrane under 225 mA for about 2 hours in transfer buffer (25 mM Tris-HCl,
190 mM glycine and 20 % methanol). Blocking the membrane prevents non-specific
background binding of the primary and secondary antibodies to the membrane. Hence, the
nitrocellulose membrane was placed into the blocking solution (filtered 5% BSA in TBST, Tris
Buffer Saline Tween20 buffer) for 40 minutes at room temperature. The membrane was then
incubated with primary antibody (mouse anti-hCA32 primary antibody) diluted with 1:1000
dilution ratio in freshly prepared blocking buffer at 4°C overnight. The next day, membrane was
washed using TBST buffer 3-4 times each time lasting 5 minutes at room temperature. The
secondary antibody (anti-mouse secondary antibody, AP conjugated), diluted in fresh blocking
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buffer with 1:10,000 dilution ratio was applied to the membrane and incubated at room
temperature for about an hour. The membrane was washed in TBST 3 times and each time lasts
5 minutes. The location of the antibody can be revealed by using a colorless substrate that
enhances once it binds to the secondary antibody and further be seen and photographed. One ml
of substrate along with 25 uL of enhancer was added to the membrane and a photo was
transferred on a film.
2.9. Relaxivity measurements
The concentrated protein samples were first allowed to dialyze and chelaxed using
10mM HEPES-Chelaxed buffer at pH7.3 for 48 hours to remove free metal ions from the
protein solution. Relaxivity measurements were taken using fixed concentration of Gd+3 and
increasing protein concentration. The T1 and T2 relaxation time of ProCA1 variants and hCA32
were measured by a Bruker Minispec relaxomter. The T1 is the time of longitudinal
magnetization recovery and T2 is the time of transverse magnetization recovery to equilibrium
along the direction magnetization. 200 ul of the solution containing varying concentrations of
contrast agents, fixed [Gd+3] and 10 mM HEPES pH 7.3 was added to a clean glass tube
specially used for this instrument. Glass tubes were incubated in the instrument until it reached
to equilibrium state and T1 and T2 values were measured. R1 and R2 were calculated using
Equation 2-2

𝑹𝟏,𝟐 =

�

𝟏
𝟏
−
�
𝑻𝟏,𝟐 𝑺𝒂𝒎𝒑𝒍𝒆 𝑻𝟏,𝟐 𝑩𝒖𝒇𝒇𝒆𝒓

[𝑮𝒅𝟑+ ]
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Equation 2-2

2.10.

Terbium Titration using Metal- Chelator Buffer System

All the acquired fluorescence spectra were recorded using a fluorescence
spectrophotometer (Photon Technology International, Inc.) with xenon short arc lamp at
ambient temperature. Luminescence resonance energy transfer (LRET) experiments for Tb3+
were acquired by tryptophan excitation at 280 nm and emission from 500 to650 nm. For the
Tb3+-EGTA or Tb3+ - DTPA buffer system 30 μM of hCA32 were added into the buffer
containing 50 mM HEPES, 150 mM NaCl, 5mM EGTA or DTPA at pH 7.2 and 0.05 uM of
Rhodamin-5N, tripotassium salt (Invitrogen Molecular Probes). Rhod-5N, tripotassium salt is a
weak calcium indicator, which can detect the presence of any free Ca2+ with a binding affinity
of 320 μM[52]. As mentioned earlier, trivalent terbium is known to selectively bind to calcium
binding sites hence calcium-binding dyes are often used to mimic similar conditions for
determining Tb3+ affinities. Since rhodamin-5N has lower binding affinity for metal, throughout
the titration the metal is either bound to chelator (EGTA or DTPA) or the protein. Rhodamin5N dye was used as an internal standard to detect the chelator (EGTA or DTPA) and protein
saturation caused by Tb3+ in the buffer system (λEx= 551 nm, λEm= 576 nm). Then, TbCl3 was
titrated into the buffer with protein. The concentrations of Free Tb3+were calculated by
Equation 2-3. The protein is excited at 280 nm so the tryptophan residue near the binding
pocket is excited and transfers energy to the bound metal Tb3+, which further has a fluorescence
emission at 545 nm. As the Tb3+ concentration increases, an increase in fluorescence intensity
must be observed due to the emission of Tb3+ bound in the vicinity of tryptophan residue.

[𝑻𝒃𝟑+ ]𝒇𝒓𝒆𝒆 = 𝑲𝒅𝑻𝒃−𝑫𝑻𝑷𝑨 ×
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[𝑻𝒃−𝑫𝑻𝑷𝑨]

[𝑫𝑻𝑷𝑨]𝒇𝒓𝒆𝒆

Equation 2-3

𝒇=

[𝑻𝒃𝟑+ ]𝒇𝒓𝒆𝒆

𝒏

[𝑲𝒅]𝑻𝒃−𝑫𝑻𝑷𝑨 𝒏 +[𝑻𝒃𝟑+ ]𝒇𝒓𝒆𝒆

𝒏

Equation 2-4

*Note: The same equations were analogously used for the buffer system with EGTA as a
chelator.
[Tb3+]free is the free Tb3+ concentration calculated from buffer system, Kd Tb, EGTA or DTPA
is the dissociation constant of Tb3+ and EGTA orTb3+andDTPA, the dissociation constants of
Tb3+ to EGTA (10-18M) and DTPA (10-22M) were obtained from NIST.[Tb-DTPA] is the
concentration of Tb-DTPA complex that is formed during titrations, [DTPA]free is the free
DTPA in the buffer, f is the fractional change, KdTb,hCA32is the dissociation constant between
Tb3+and hCA32.
2.11.

Determining Metal Binding Affinity: Gd3+, Zn2+, Ca2+, Lu3+

All the acquired fluorescence spectra were recorded using a fluorescence
spectrophotometer (Photon Technology International, Inc.) with xenon short arc lamp at
ambient temperature. As gadolinium does not fluoresce, terbium fluorescence was utilized via
LRET competition method to measure the Gd3+binding affinity to hCA32. The terbium
fluorescence spectra were acquired by tryptophan excitation at 280 nm and emission from 500
to650 nm. 10 μM of hCA32 and 20 μM Tb3+were incubated with 0 to 1000 μM of GdCl3 at
room temperature over night. The Tb3+FRET changes were measured by the emission at 545
nm. The apparent Kd‘s were fitted by 1 to 1 binding Equation and Kd of Gd3+were calculated by
Equation 2-5 and Equation 2-6 and the Kd hProCA32-Gd3+ was calculated using Equation2-7
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𝚫𝒇 =

𝚫𝒇 =

(𝑷𝑻 +𝑴𝑻 +𝑲𝒅 )−�(𝑷𝑻 +𝑴𝑻 +𝑲𝒅 )𝟐 −𝟒𝑷𝑻 𝑴𝑻

Equation 2-5

𝟏−(𝑴𝟐 +𝑴𝟎 +𝑴𝟏 )−�(𝑴𝟐 +𝑴𝟎 +𝑴𝟏 )𝟐 −𝟒𝑴𝟐 𝑴𝟎

Equation 2-6

𝟐𝑷𝑻

𝟐𝑴𝟐

𝑲𝒉𝑷𝒓𝒐𝑪𝑨𝟑𝟐−𝑮𝒅 = 𝑲𝒂𝒑𝒑 𝑲

𝑲𝒅𝟏

𝒅𝟏 +[𝑻𝒃

𝟑+ ]

Equation 2-7

𝑻𝒐𝒕𝒂𝒍

Gadolinium binding of hCA32 was also determined by competition titration using
Fluo5N dye. Fluo-5N (Invitrogen Molecular Probes) is used as gadolinium indicator with a Kd
of 3.8 × 10-12 M [29]. The Fluo-5N emission spectra were obtained by excitation at 488 nm and
emission from 500-650 nm. Fluo-5N and Gd3+ were mixed with 1:1 (2-4 μM) ratio in 10 mM
HEPES at pH 7.0 and Protein was gradually titrated into the cuvette. As protein concentration
increases in the system, the protein competes with the dye causing a decrease in the
fluorescence signal. The signal decreases until the protein is saturated. The fluorescence
intensity decrease of Fluo-5N at 520 nm with titration of various hCA32 concentrations were
fitted using one to one binding equation, Equation 2-5 to get an apparent dissociation constant
Kapp . The Gd3+ binding affinity of hCA32 was calculated using Equation 2-8where Kd1 is the
binding affinity of Fluo-5N and Gd3+.

𝑲𝒉𝑷𝒓𝒐𝑪𝑨𝟑𝟐−𝑮𝒅 = 𝑲𝒂𝒑𝒑 𝑲

𝑲𝒅𝟏

𝒅𝟏 +[𝑭𝒍𝒖𝒐−𝟓𝑵]𝑻𝒐𝒕𝒂𝒍

Equation 2-8

The Zinc binding affinity of ProCA1 variants and hCA32 were determined using a
similar assay by competition titration using FluoZin1 dye (Invitrogen Molecular Probes). The
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binding affinity of contrast agents for zinc must be comparatively low, as zinc is present in
physiological conditions, which can hinder the formation of ProCA-Gd3+ complex may affects
the relaxation rate and MRI signals. In order to obtain the binding affinities of Zn2+,various
concentrations of contrast agents were gradually titrated into the 1:1 dye-metal complex (FluZn1-Zn2+)to compete for the Zn2+ ions bound to the dye. Fluorescence emission spectra of
FluoZin1 were obtained from 500-600 nm with an excitation at 495 nm and decrease in
intensities was monitored at 515 nm. Apparent Kd was obtained by fitting the data using one to
one binding equation, Equation 2-5. The following equation was used to calculate the Kd value
of hCA32-Zn binding where kd1 is the binding affinity of FluoZin1 and Zn2+ (2.2× 10-12 M) [29].

𝑲𝒉𝑷𝒓𝒐𝑪𝑨𝟑𝟐−𝒁𝒏 = 𝑲𝒂𝒑𝒑 𝑲

𝑲𝒅𝟏

𝒅𝟏 +[𝑭𝒍𝒖𝒐𝒁𝒊𝒏−𝟏]𝑻𝒐𝒕𝒂𝒍

Equation 2-9

For determining the calcium binding affinity of hCA32, calcium equilibrium buffer
system was used where, 5 μM hCA32 was added to the calcium –EGTA buffer system
containing 50 mM HEPES, 150 mM NaCl, 5 mM EGTA, pH 7.2. Various calcium chloride
concentrations were titrated to the buffer system. Free calcium concentrations in the buffer were
tightly monitored and calculated using equation derived from tsein’s equation (Equation 2-10)
where Kd of EGTA-Ca2+ =1.51x10-7 M was obtained from NIST[53].

[𝑪𝒂𝟐+ ]𝒇𝒓𝒆𝒆 = 𝑲𝒅𝑪𝒂−𝑬𝑮𝑻𝑨 ×
2.12.

[𝑪𝒂−𝑬𝑮𝑻𝑨]
[𝑬𝑮𝑻𝑨]𝒇𝒓𝒆𝒆

Equation 2-10

PEGylation

To optimize the protein solubility, blood circulation time, avoid possible enzymatic
degradation and reduction of immunogenicity; Poly ethylene glycol (PEG) conjugation with
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protein has been often used in pharmaceutical and biotechnical applications. The desired protein
can be modified using several PEG conjugation strategies such as amino group modification,
thiol group modification. hCA32 has been PEGylated with NHS-Ester on lysine residue and
PEG-Maleimide on cysteine residue. The detailed procedures are in the following sub section.
2.12.1. Lys-PEG
The contrast agent was modified using Methyl-POEn-NHS ester, PEG-40 (Thermo
Scientific Pierce) with molecular weight of 2.34 kDa and 40 repeating units of ethylene glycol.
At first, hCA32 and PEG-40 (Pierce) were mixed with1:5 ratios in 10 mM HEPES buffer (pH
7.2)and allowed to shake at room temperature for about 2 hours or at 4 °C overnight. Further,
100 mM Tris/HCL was added to the reaction system in order to stop the reaction by quenching
the unreacted free PEG-NHS ester. The mixture was then concentrated about 4 times using
amicon nitrogen concentrator with 3kDa membrane to remove the unreacted free PEG (MW
2.34 kDa). The PEGylated protein was identified by Iodine staining and SDS-PAGE. Iodine
can stain the free PEGylated protein along with free PEG in the solution while Coomassie
brilliant blue can stain the protein that is already conjugated with PEG.
2.12.2. Cys- PEG
The PEGylation of free and unessential cysteine residues in the protein is another
approach that is gaining popularity. Majority of protein naturally contains multiple lysine
residues as a result multiple isomers can be formed when modified with lys-PEG. In order to
avoid such complications, PEG modification at cysteine can be used to attain homogeneity. If a
primary amino acid sequence of a protein lacks cysteine residue, it can be easily introduced via
genetic engineering and molecular cloning. At first, the protein with concentration of about 1-10
mg/ml was dissolved in 10 mM HEPES buffer, pH 7.2. This solution was flushed with inert gas
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such as nitrogen, argon or helium gas. Access of TCEP (Tris-carboxyethylphosphine) reagent
(Thermo Scientific Pierce), 1:10 volume ration was added to reduce the disulfide bonds in the
presence of inert gas. This mixture was left on a shaker for 20 minutes at room temperature.
Methyl-PEG Maleimide reagent (Thermo Scientific Pierce and JenKem Technology) with
molecular weights of 0.710 kDa, 1.2 kDa, 2kDa and 5kDA were added to the buffered hCA32
mixture with a ratio of 1:5 in the presence of inert gas and the tube was closed tightly to avoid
the escaping of gas. The solution was left shaking overnight at 4 °C.
2.13.

Serum Stability

The serum stability test is one of the useful tests to confirm the stability of an unstable
biological compound in vitro. The serum stability of 2kDA-PEGylated and non-PEGylated
hCA32 was analyzed by incubating the designed protein in a complex form with an equal
concentration of GdCl3 in mice serum at 37 °C.hProCA32-Gd3+ (500 μM) was mixed with mice
serum with 1:1 ratio and incubated at 37 °C for 12 days. During this time frame 10 μL of
samples were collected at various time points. These samples were analyzed by SDS-PAGE and
western blot to confirm the stability of the protein.
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3. DEVELOPMENT OF RAT PROCA1 AND ITS ENGINEERED VARIANTS VIA
GRAFTING APPROACHES
3.1. Introduction
As discussed in Chapter 1 (Section 1.7), Dr. Yang’s Lab has developed a series of
protein-based molecular imaging contrast agents by constructing a metal binding pocket, which
in our case is for gadolinium. The scaffold protein, domain 1 of rat CD2 was selected by
keeping its physical characteristic such as stability, solubility and molecular size into
consideration. The first generation of protein-based MRI contrast agent (ProCA1), developed
and analyzed by previous lab members, has high r1 and r2 relaxivities compared with the clinical
contrast agents both in vitro and in vivo[29]. In order to enhance the diagnostic capabilities of
our contrast agent for the early detection of cancer, ProCA1 was targeted with affibody that can
recognize the biomarkers EGFR and HER2 in breast cancer cells [10]. In our approach to
broaden the horizon of the capability of ProCA1 to target the diseased biomarkers; we have
further modified the contrast agent with GRP to target the receptor GRPR, which is highly
expressed on prostate cancer cells. Initially, ProCA1 was modified in two different ways: (1) by
adding GRP at C-terminal (ProCA1.GRPC), and (2) by grafting GRP between Glys52 and
Gly53 (ProCA1.GRP (52)) in the protein sequence. Amongst these two variants, ProCA1.GRP
(52) showed higher metal binding affinity for Gd3+ and stronger in vivo biomarker targeting
capability as compared to ProCA1.GRPC with detection of GRPR expressed on, as low as 107
cancer cells (tumor size of < 0.3 cm)[27]. So to improve the GRPR targeting capability of
ProCA1, various lengths of GRP peptides native to mammalian cells or bombesin peptide,
found in amphibians were grafted into ProCA1. In order to move further with the in vivo
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studies, the production process of the contrast agents must be optimized to yield high quality,
stable and well-folded ProCAs.
In this chapter, the bacterial E.coli expression in LB medium and tagless purification
process of targeted ProCA1 variants namely ProCA1.G10, ProCA1.B10 and ProCA1.B14 are
described. Further, the relaxivity studies and zinc binding affinities of these variants are
presented.
3.1. Results
3.1.1. Expression of ProCA1 and its variants

ProCA1 and its variants were cloned into a tagless vector pET20b (+) by previous lab
members, as mentioned earlier in the section 2.1.1. These variants were first expressed at a
small-scale level in 10 mL of LB medium to optimize the expression conditions. Small Scale
expression is usually performed to attain higher yield by establishing suitable conditions.
Another important purpose of doing small-scale expression is to monitor the expression of
ProCA1 in two E.colicell strains; BL21 (DE3) and Tuner. Initially three clones were selected
from agar plates with ProCA1 cloned into BL21 (DE3) and Tuner. These selected colonies were
expressed using the protocol described in sections 2.1.3 and 2.1.4. The overexpression of
ProCA1 in these colonies is shown in the Figure 3.1A and Figure 3.1B. A typical process for
bacterial growth of E.coli cells has four stages, namely, lag phase, log phase, stationary phase
and death phase. The cellular growth curve shows an exponential increase with time in minutes
(Figure 3.1 C and D). In SDS-PAGE gel (Figure 3.1A) a slight band at ~ 11 kDa in the
samples for before-induction (lanes 1 and 3) indicates the occurrence of leaky expression in
BL21DE3 cell strain. However, a bright band at 11 kDa is observed for all the clones picked
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(lanes 2,4 and 6) after the IPTG induction and temperature reduction to 25°C. Similar
phenomenon was observed for protein expressed in Tuner cell strain, colonies 1 and 2 (lanes 14) (Figure 3.1 B). Tuner cell strain has a tendency to produce inclusion bodies, which
acclimates the expressed protein and sediment with the pellet. Intense bands around 25 kDa in
SDS PAGE gel indicates that along with the desired protein ProCA1, other unwanted proteins
were also expressed in higher quantity as compared to ProCA1 (11kDa). Large-scale expression
was performed using the remaining samples of the selected cell strains. Although the optical
density curve for BL21 (DE3) at 37 °C was exponential, a low level expression was seen after
the induction with 1 mM IPTG induction. Thus, reducing the temperature did not have any
significant effect on the expression level. This could have happened either due to bad quality of
the cloned selected or contamination of the growth medium.

62

ProCA1 BL21(DE3) cell strain

A

5

B

Colony1 Colony2 Colony3

7E15 BL1
7E15BL2
7e15BL3

Absorbance

4

BL21(DE3)

26
2

OD

600

68

IPTG

3

14

1

0

6
0

200

400 600 800
Time (min)

1000 1200

ProCA1 in Tuner cell strain
6

C

600

Absorbance

5

OD

D

7E15Tuner1
7e15tuner2
7E15Tuner 3

4

68

Colony1 Colony2 Colony3

Tuner

IPTG

3

26

26

14
6

14
6

2
1
0

68

0

200

400

600

800

1000 1200

Time (min)

Figure 3.1Small scale expression of ProCA1 in various E.colicell strains
A) Small scale expression gel of ProCA1 in Bl21DE3 cell strain, where M is Marker with
standard molecular weight, 1, 3 and 5 are before induction and 2,4,6 are after induction
for colonies a, b and c respectively. B) Small scale expression gel of ProCA1 in Tuner cell
strain, where M is Marker, 1, 3 and 5 are before induction and 2,4,6 are after induction
for colonies a, b and c respectively. C) Cellular growth plot at various time periods during
the expression of ProCA1 in BL21DE3 cell strain. D)Optical density during the cellular
growth at various time periods during the expression of ProCA1 in Tuner cell strain.

*Note: All the samples added to gel electrophoresis are of equal volume of the culture.
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Subsequently, Large-scale expression of ProCA1 was performed using the
aforementioned protocol in BL21 (DE3) and Tuner E.coli cell strains in LB medium. The
expression level of ProCA1 in BL21 (DE3) cell strain was optimized by various IPTG
concentrations administered at induction. The exponential increase in optical density to the
point of induction for ProCA1 in BL21 (DE3) indicates a bacterial cell growth throughout the
expression process (Figure 3.A). A distinct band is observed at around 11 kDa prior to
induction indicates the occurrence of a residual “leaky” expression in BL21 (DE3)(Figure 3.B).
Such leaky expression is caused due to initiation of transcription in the absence of inducer and
is also known as basal expression [54]. There are many possible reasons that may lead to leaky
expression; the Lac repressor protein does not bind to the DNA efficiently and remains unable
to shut off the gene transcription from the lac operator promoter. The expression cloning
constructs such as pET, pUC etc. are often made to generate high copy number of plasmid
which may further lead to the potentially increase in the copy number of promoter and operator
causing leaky or basal expression[54, 55]. At induction, the cells received various
concentrations of IPTG, 0.1 mM, 0.3 mM, 0.5 mM and 1.0 mM and were allowed to express at
30 °C overnight until harvesting. All the IPTG concentrations seemed to have similar effect on
the expression as thick bands are observed after the overnight expression at 30 °C (Figure
3.2B).
In case of large-scale expression of ProCA1 in Tuner cell strains, their expression level
was comparable to that of samples expressed in BL21 (DE3) Tuner cell strain is a mutant of
BL21 with a deletion of lacZY, a mutation of lac permease (lacY). Such mutation allows the
uniform entry of an inducer, which in our case is IPTG into the cell throughout the cultured
medium making the induction in a true concentration dependent fashion[56].Hence, the
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expression can be regulated and improved by increasing the inducer, IPTG concentrations.
Instead of testing the effects of various concentrations of IPTG as in case of BL21 (DE3) cell
strains, maximum amount of IPTG (1mM) was used for the large-scale protein expression in
Tuner cell strains. The optical density curve increased exponentially to the point of induction
indicating a fairly well bacterial growth (Figure 3.2C). A faint band at 11 kDa is observed in
SDS-PAGE gel suggesting the occurrence of leaky expression (Figure 3.2 D). High optical
density value after the overnight expression at 30 °C indicates that Tuner cells produced a large
amount of inclusion bodies with a net pellet weight of 5.91 g/L. However, thick bands 25 kDa
to 60 kDa in SDS-PAGE gel suggests that a large amount of unknown proteins were coexpressed along with the desired protein.
All the targeted ProCA1 variants, ProCA1.G10, ProCA1.B10, and ProCA1.B14 were all
overexpressed in BL21 (DE3) competent cells. As seen in Figure 3.3, all the variants seem to
have clear bands at 12 kDa in SDS-PAGE gel both before and after 1 mM IPTG induction.
ProCA1.B14 has a cysteine in the targeting peptide grafted on ProCA1, which can possibly
form a disulfide bond resulting into dimerization of the protein expressed. Hence, a distinct,
bright band is observed at ~ 24 kDa in SDS-PAGE gel (Figure 3.3 C) both before and after
induction where the SDS sample buffer did not contain any reducing reagent
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Figure 3.2 Large scale Expression of ProCA1 in E.coli cell strains using LB medium.
((A) Cellular growth curve and (B) 15 % SDS-PAGE of ProCA1 expressed in BL 21(DE3)
with before and after induction where various IPTG concentrations were used for the
samples for after induction (0.1mM, 0.3 mM 0.5 mM and 1 mM). (C) Cellular growth
curve (D) 15 % SDS-PAGE of ProCA1 expressed in Tuner.

*Note: All the samples added to gel electrophoresis are of equal volume of the culture.

66

Figure 3.315 % SDS-PAGE of the overexpression of (A) ProCA1.B10, (B) ProCA1.G10
and (C) ProCA1.B14 in Bl21 (DE3) competent cells.
Before induction and after induction by 1mM IPTG has evidenced difference in the band
intensity at ~12 kDa.(C) For ProCA1.B14, dimer form of the protein is observed at ~24
kDa.The SDS sample buffer did not contain any reducing reagent and the SDS gel was a
non-reducing gel.

*Note: All the samples added to gel electrophoresis are of equal volume.
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3.1.2. Tagless purification by denaturing and refolding method
ProCA1 variants expressed in LB medium were purified using the procedure described
in Figure 2.3 (Section 2.2). After harvesting the cell pellet, it was suspended in 30 mL of PBS
for cell lysis. Subsequently, the homogenized cell lysis was achieved by the use of sonication
followed by cell disruptor. The inclusion bodies formed during the expression were found in the
pellet after breaking the cells (Figure 3.5 A). The purification process for ProCA1 expressed
using BL21 (DE3) competent cells illustrated in Figure 3.5. During the rapid expression of the
protein, large amounts of cellular components and broken cell membranes are expressed which,
after breaking of cell membrane, are released into the cell lysis solution and remain in the pellet
along with the protein after centrifugation. Detergents are widely used to isolate the protein
from cell membrane as stabilizing and denaturing reagents [57]. Triton x100 is often used for
solubilizing the lipid bilayer in the cell lysis by interacting with the polar group present on the
hydrogen-bonding region. In our case, Triton x100 can be used to solubilize the insoluble lipids
bilayer that coexists along with the desired protein in the pellet. In order to get rid these lipids
and insoluble waste, the pellet is re-suspended three times into 2 % of Triton 100 X where the
protein remains insoluble in the pellet. Due to the presence of large amount of hydrophobic
lipids in the protein solution, the clarity of the protein band in SDS gel can be affected. This
clarity of the protein band in pellet seems to improve after the 2ndtriton application. SDS-PAGE
gel (Figure 3.5 A) shows a bright band at ~11 kDa (in the pellet), indicating that majority of
unwanted materials and proteins were indeed solubilized and discarded into the supernatant
while the desired contrast agent remained in the pellet. Some of the ProCA1 seemed to be
eliminated along with the waste, which might have been due to following reasons: 1) Triton 100
X could be a little harsh for the protein, if the protein solution is washed for too long the
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detergent may denature it. 2) The solution might not be homogeneous prior to the centrifugation
that may lead to improper separation of the pellet and supernatant 3) Error in preparing the SDS
sample where the samples were not centrifuged properly to separate completely the supernatant
from the pellet. Again due to rapid expression as inclusion bodies, a lot of protein molecules
may have misfolded. Thus, the precipitates obtained were allowed to solubilize in 8 M urea
causing the protein to unfold completely from its native folding. The soluble protein was
separated in the supernatant from the insoluble waste. The next step was the gradual refolding
of the protein by dialysis in reducing urea concentration from 4 M urea to 2 M urea followed by
0 M urea (10 mM Tris at pH8.0). As seen SDS-PAGE gel (Figure 3.5B), the lone high-density
band is seen at 11 kDa after dialysis suggesting that the majority of the solution consisted of
ProCA1. The next step is to remove any possible small fragments of waste and DNA using
anion exchange chromatography. The Äkta-FPLC system and Hi-Trap Q column packed with
sepharose are washed and recharged using the procedure described in section 2.2.2. After
washing the column with high salt containing buffer B (10 mM HEPES, 1.0 M NaCl at pH 8.0)
followed by buffer A (10mM HEPES at pH 8.0), protein solution filtered with 0.45 mm
Millipore membrane filter was injected into the system. The first step is the binding step where
the negatively charged residues on ProCA1 bound to the positively charged column for 5
column volumes (CV). The salt gradient was introduced to 35 % for 1 CV followed by a
gradual increase to 40 % over another 2 CV. The salt gradient was held at 40 % for next 2 CV
until it reached to 100 % buffer B. The protein had negatively charged residues but the total
negative charge was not as much as nucleic acids. Hence, the protein was expected to elute at
lower salt content.
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Figure 3.4 Salt gradient program for the isolation of ProCA1 variants using anion
exchange Q column in FPLC.

As seen in the FPLC chromatogram of ProCA1 expressed in BL21 (DE3) (Figure3.5C),
four peaks were observed. SDS-PAGE gel of the fractions indicated that majority of the
ProCA1 indeed eluted out as the salt concentration increased, under peak 2. Peak 3 and 4 are
not well separated as seen in the spectrum; however, the SDS gel demonstrates that both peak 3
and 4 contains our desired protein (Figure 3.5 B). Since the anion exchange chromatography
separates each component based on its charge, it can be concluded that elution under peak 3 and
4 are more negatively charged as compared to the elution under peak 2, which might be due to
DNA contamination. Hence, although the SDS-PAGE gel is indicative of the presence of the
protein in peak 3 and 4, it is obvious that both the peaks contain a mixture of protein and DNA.
Some of the protein also elutes out under peak 3 (Figure 3.5 B). Therefore, ProCA1 expressed
in BL21 (DE3) cells was extracted in its pure form under peak 2 using tagless purification and
anion exchange chromatography. Another batch of ProCA1 was expressed in BL21 (DE3) and
purified. The FPLC spectrum (top) and the 15 SDS gel (bottom) of Figure 3.6shows that
protein eluted under peak 2.
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Figure 3.5Tageless Purification of ProCA1 expressed in BL21 (DE3) competent cells by
Refolding method
(A) 15 % SDS PAGE: The first step of the purification by washing the cell pellet in 2 %
Triton 100 X. The protein band brightens by the third wash. (B) 15 % SDS-PAGE: The
second step of purification by denaturing the protein to make it soluble along with
removing other unwanted waste that is insoluble or denatured in the cell pellet. Gradually
refolding the protein by dialyzing it in reducing urea concentration of the buffer. (C) The
final step of the purification by anion exchange Q- column using FPLC to eliminate small
molecular weight, unwanted components that co-exists in the solution.
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Figure 3.6 Purification by FPLC of another batch of ProCA1 expressed in BL21 (DE3)
competent cells
The FPLC spectrum shows 3 major peaks where the protein eluted out under peak 2.
Peak 2 was divided into two separate portions: 2a-fractions under high Uv absorbance
and 2b) fractions under the tailing part of the peak as it may contain DNA in it. The 15 %
SDS gel confirms the presence of ProCA1 under peak 2a
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Three major peaks are observed in the FPLC spectrum for ProCA1 expressed in Tuner
cell strains. In comparison with ProCA1 expressed in BL21 (DE3) cells, Tuner cells had a large
amount of DNA expressed in the inclusion bodies. If the protein solution, prior to anion
exchange chromatography contains large amount of DNA/RNA or nucleic acid fragments that
have morenegative charge as compared to protein (ProCA1), it may compete with the protein
during the binding process hindering the protein to bind to the column. So due to the presence
of large amount of nucleic acids in the protein solution expressed in Tuner cells, the protein was
unable to bind with the column as result high UV absorbance is observed during the binding
step of the FPLC program (Figure 3.7 C). Furthermore, the UV spectrum of elution under peak
1 has high absorbance at 280 nm whereas the elution under peak 2 has high absorbance at 260
nm suggesting that peak 1 had majority of protein compared to peak 2 (Figure 3.7 B), which is
supported by the presence of band at 11 kDa in SDS-PAGE gel (Figure 3.7 A). A slight
shoulder in Peak 2 is observed in the FPLC spectrum, which suggests that the fractions under
the shoulder may contain some DNA.
The GRPR targeted ProCA1 variants (ProCA1.G10, ProCA1.B10 and ProCA1.B14)
inserted with various targeting moieties were expressed in BL21 (DE3) and purified using
tagless purification protocol mentioned in Figure 2.3 (Section 2.2). The purification results for
each variant are shown in the Figure 3.8-3.10
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Figure 3.7 The tagless purification of ProCA1 expressed in Tuner cell strain by refolding
method.
(A) SDS-PAGE gel after solubilizing it in 8 M urea and refolding it gradually by dialysis in
reducing urea concentrations. (B) UV spectra of peak 1 and peak 2 separated by FPLC.
(C) The FPLC chromatogram of ProCA1 expressed in Tuner.
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Figure 3.8 15 % SDS PAGE depicting the purification steps of ProCA1.G10
(A) The first and second step of purification by 3 times 2 % Triton 100 X and unfolding of
the cell pellet by 8 M Urea. Majority of the unwanted protein at 26 kDa still coexisted
prior to FPLC injection. (B) The SDS-PAGE of the fractions under FPLC spectrum where
majority of the protein was isolated under peak 2 and peak 3.
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Figure 3.9 15 % SDS PAGE depicting the purification steps of ProCA1.B14 expressed in
BL21(DE3) cell strain
A) 15 % SDS- PAGE of the first and second step of purification by 3 times 2 % Triton 100
X and unfolding of the pellet by 8 M Urea. Some of the unwanted proteins were removed
in the pellet separated after dialysis suggesting that exposure to 8M urea was too harsh
causing them to degrade or the proteins were unable to refold back after being denatured
by 8M Urea. However, the presence of SDS bands between 14 kDa and 26 kDa and at 68
kDa indicates that some wanted protein were indeed refolded back along with
ProCA1.B14. (B) The SDS-PAGE of the fractions from FPLC spectrum shows that the
majority of the protein was isolated under peak 2 and peak 3.
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Figure 3.10 15 % SDS-PAGE analysis of the purification process of ProCA1.B10
expressed in BL21(DE3) E.coli cell strain.
A) 15 % SDS- PAGE of the samples after sonication shows that ProCA1.B10 remained in
pellet (band at 12 kDa) and first wash with 2 % Triton 100 X removed some unwanted
proteins (bands at 55 kDa). (B) The band at 12 kDa are enhanced and brightened (in the
pellet) due to the removal of lipids by the remaining two Triton wash. After unfolding of
the protein solutionby 8 M urea the band intensity at 25 kDa reduced suggesting that
those protein were unable to fold back after being denatured.(B) The FPLC fractions
under peak 2 were separated as The SDS-PAGE of the fractions from FPLC spectrum
shows that the majority of the protein was isolated under peak 2a.
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Figure 3.11Western Blot and 15 % SDS- PAGE of purified ProCA1 variants.
(A) Western blot of the concentrated samples of ProCA1 variants identified by anti
hCA32 primary antibody. (B) 15 % SDS PAGE of the concentrated samples of ProCA1
variants.

Table 3.1 Final yields of the ProCA1 variants purified using tagless refolding method.
Final Volume Final concentration Final yield
ml
μM
(mg/L)
ProCA1.B14

5.00

94.87

6.33

ProCA1.G10

15.0

97.86

18.82

ProCA1

10

134

14.94

ProCA1.B10

6.00

122.8

9.45
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SDS-PAGE analysis of each purified ProCA1 variants indicates that the proteins were
isolated in its pure form (Figure3.11 B). However, two smeared bands at 12 kDa for
ProCA1.G10 suggest that there was degradation. This was further supported by the western blot
result, as western blot is a sensitive technique that can identify a very tiny amount of protein
with a series of primary and secondary antibodies bound to it (Figure 3.11 A). ForProCA1.B10,
a bright band is observed at around 24 kDa, which can be justified as a dimer form. Although
ProCA1.B10 does not contain cysteine ruling out the possibility of forming a disulfide bond,
this dimer could have possibly formed due to protein-protein hydrophobic interactions
3.1.3. Determination of Relaxivity
As discussed in chapter 1, relaxivity is a technical term used for MR Imaging to describe
the ability of a contrast agent to utilize paramagnetic metal ions and increase the relaxation rate
of the surrounding water proton spins per concentration of a contrast agent under magnetic
field[58]. Many factors affect the relaxivity of a contrast agent such as the strength of magnetic
field, interactions with water and gadolinium, molecular size, flexibility or rigidity of the
contrast agent, protein-metal interactions. In this part of the work, relaxivity of ProCA1 variant
was measured using 60 MHz relaxometer (Bruker). Each protein samples were chelaxed to
eliminate free metal ions present in the solution that may cause hindrance. Each ProCA1 variant
was incubated with various concentrations of Gd3+, ranging from 1μM to 50 μM in 10 mM
HEPES at pH 7.2. ProCA1 variants have one engineered binding pocket containing negatively
charged residues that can interact with the Gd3+and water molecule. These interactions in the
presence of a magnetic field are measured as T1 and T2 relaxation times, and the relaxometer
gives these values in microseconds (μs). The T1 and T2 measurements of the buffer with no
Gd3+were used as a control. The relaxation rate is inversely proportional to the relaxation time
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(1/T1 or 1/T2). These measurements were plotted on a graph as a function of the Gd3+ in molar
concentration. The R1 and R2 relaxivities were calculated using Equation3-1

𝑹𝟏,𝟐 =

�

𝟏
𝟏
−
�
𝑻𝟏,𝟐 𝑺𝒂𝒎𝒑𝒍𝒆 𝑻𝟏,𝟐 𝑩𝒖𝒇𝒇𝒆𝒓
Equation 3-1
[𝑮𝒅𝟑+ ]𝑻𝒐𝒕𝒂𝒍

The relaxivity of ProCA1 variants measured at three different temperatures, 25°C, 30°C
and 37°C are shown in Figure 3.12. Relaxivity of a contrast agent can be affected by a change
in temperature. As the temperature increases, the tumbling rate of a contrast agent increases
causing an increase in the relaxation times. All ProCA1 variants showed much higher
relaxivities (25.9-49.2 mM-1s-1) as compared to the clinical contrast agent such as Magnevist
(Gd-DTPA: 3.5 and 5 mM-1s-1). ProCA1G10, ProCA1B10 and ProCA1B14have much higher
relaxivitiesthanthat of ProCA1. Such drastic difference in the relaxivity could be due to the
additional targeting sequence grafted onto the scaffold protein influencing the tumbling and
movement of the contrast agent. In addition, it can also be concluded that the linker connecting
the grafted peptide and the scaffold ProCA1 enables the ProCA1 moiety to move freely without
being hindered or restricted by the grafted peptide on the C-terminal of ProCA1. This indicates
that ProCA1 variants require less local concentration or dosage to improve the contrast of tissue
compared to that of clinical MRI contrast agents. Due to this high relaxivity, our contrast agent
can target the cancer biomarkers that have 103-06 receptors per cell and give out detailed
information with improved sensitivity of MR images and high resolution.
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Figure 3.12 Relaxivity measurements of ProCA1 variants.
(A) The relaxivity of ProCA1 variants (ProCA1, ProCA1.G10 and ProCA1.B10) measured
at 25°C. (B) The relaxivity measurements of PRoCA1 variants at 30 °C. It’s clear that the
relaxation property of the targeted contrast agent is enhanced due to the additional
sequence. (C) The relaxivity measurements of ProCA1 variants at 37 °C compared with
the relaxivity of Magnevist (Gd-DTPA) a commercially available contrast agent.
Relaxivity of ProCA1 variants are much high compared to Gd-DTPA. There is no
significant difference in the relaxivity of ProCA1.B10 and ProCA1.B14 despite of the
sequence differences. Non-targeted ProCA1 seems to have a decrease in the relaxivities,
this could have been either due to an error in preparing samples or the quality of the
protein has been affected due to degradation.
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3.1.4. Fluo-Zn competition assay
Zinc is one of the major physiological metal ions, which is potentially involved in
transmetallation and thereby possibly removing the Gd3+from contrast agents. The clinical MRI
contrast agent DTPA has a relatively high affinity for Zn2+(6.3 × 10-19 M), to that for Gd3+(1.9 ×
10-21 M) (NIST). To further understand and analyze any possibility of competition amongst the
two ions in vivo, it is crucial to test the metal selectivity of our contrast agent. Dr. Yang’s Lab
has previously studied binding affinities of ProCA1 with various metals, and the reported Kd of
ProCA1-Zn2+ is 1.9 × 10-7 M [29]. The Zn2+ binding affinity of targeted ProCA1 variants were
determined using Fluozin-1 competition assay as described in chapter 2 (section 2.11). Initially,
one μM of zinc and one μM of Fluozin-1 dye were incubated in 50 mM HEPES, and 150 mM
NaCl at pH 7.2 and their fluorescence spectra were obtained. Then, various concentrations of
ProCA1 variants (ProCA1. B10 or ProCA1.G10) were titrated to the buffer-dye solution. The
contrast agent competes with the dye for Zn2+, causing a decrease in the fluorescence intensity
(Figure 3.13). The binding affinity for zinc is calculated using the following Equation 3-2

𝑲𝒅𝟐 = 𝑲 ×

𝑲𝒅𝟏

𝑲𝒅𝟏+[𝑭𝒍𝒖𝒐𝒛𝒊𝒏−𝟏]𝑻

Equation 3-2

Kapp is the apparent Kd of contrast agent for Zn2+, and Kd1 is the binding affinity of the

dye Fluo-Zn1 for zinc and the total concentration of Fluozin-1. The zinc-binding affinity of
ProCA1.G10 and ProCA1.B10 were thus determined to be 2.51 x 10-6 M and 1.08 x 10-6 M
respectively.
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Figure 3.13 Determination of Zn2+ binding affnity of ProCA1 variants using Fluo-Zn1 dye
comptetiton assay.
Fluorescence spectra of zinc binding competition assay for (A) ProCA1.B10 and (C)
ProCA1.G10 using FluoZn-1 dye.
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3.2. Conclusions
A rapid and efficient method to express and purify the first generation of ProCA and its
targeted variants has been successfully established by isolating the protein from inclusion
bodies. Suitable competent cells, appropriate temperature and dosage of inducer are important
key factors that affect the growth of bacterial cells, quality and the yield of the recombinant
target protein. The first step, overexpression of ProCA1 in inclusion bodies has been
successfully performed following the procedures designed (Chapter 2). As the data show, all
ProCA1 variants were expressed well in E.coli BL21 (DE3) competent cells as inclusion bodies
with the addition of 1 mM IPTG and temperature reduction to 25°C post induction. Although
Tuner cell strains are well known to generate high amounts of inclusion bodies, somehow the
inclusion bodies have an accumulation of DNA/RNA and nucleic acids fragments, which made
the isolation of pure protein difficult.
Purification of the highly expressed proteins in inclusion bodies was performed.
Protocols included several washing steps wit Triton 100X. Triton 100X is a mild detergent that
can solubilize lipids and cell membrane fragments that co-exist with the target protein in the
inclusion bodies after cell lysis. Washing with 2 % Triton 100X was done until the appearance
of the pellet changed from pale brown to white indicating the removal of unwanted cellular
components. All ProCA1 variants yielded clean white pellets after three washes with Triton. In
fact, such treatment enhanced the brightness of the band intensity in SDS-PAGE. The rapid
expression of large amounts of these proteins in the bacterial system has high chances of
generating misfolded protein. Hence, in our approach to solubilize the misfolded protein from
inclusion bodies using denaturant such as 8 M urea plays in our favor. Urea not only unfolds
and solubilizes the target protein but also helped in removing other unwanted proteins and
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impurities. Furthermore, proper refolding of the protein can be done to achieve high quality.
Refolding process was done by gradually reducing urea concentrations in the buffer that was
used for dialysis. The following step was to purify using FPLC to remove any remaining
impurities and nucleic acids. Using HiTrap anion exchange Q column, the protein eluted, as the
salt gradient was introduced and increased up to 40 %; nucleic acids eluted out at 100 % salt
gradient. As summarized in Table 3.1, the final yield of all ProCA1 varied from 6 mg/L to 19
mg/L. The tagless purification protocol requires repeated washing of the inclusion bodies and
centrifugation after each wash, where a lot of protein is washed out along with the impurities, as
is apparent in the 15 % SDS-PAGE gel patterns.
The GRPR-targeted ProCA1 variants have high R1 and R2relaxivities at 25° C, 30°
C and 37 °C in comparison with the Gd-DTPA, a commercial contrast agent. In fact, the
relaxivities of the targeted variants is much higher than that of non-targeted ProCA1. Such
marked difference in the relaxivity could be due to the additional targeting sequence grafted
onto the scaffold protein perhaps influencing the tumbling movement of the contrast agent.
Such high relaxivities suggests that our designed contrast agent, ProCA1 might have higher
sensitivity, and thus could achieve enhanced images at lower local concentrations. In
addition, the zinc-binding affinity of the targeted ProCA1 variants are very similar to the
reported Kd for ProCA1- Zn2+, in the range of 10-6 – 10 7, and much weaker compared to the
reported Gd3+ binding affinity of ProCA1 in range of 10-13 M[29]. The zinc binding affinities
are preliminary and should be repeated in future along testing the gadolinium binding affinity
of the targeted ProCA1.

.
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4. OPTIMIZING THE EXPRESSION AND PURIFICATION OF HUMANIZED
PROCA32 AND ITS MUTANT
4.1. Introduction
As discussed in chapter 1, ProCA32 is further humanized with engineered mutations on
the human sequence of α parvalbumin. In order to obtain a high quality contrast agent for the
biophysical characterization and animal model studies, it is extremely important to design a
well-established, time-effective, cost efficient protocol for achieving high yields of purified
humanized ProCA32 (hProCA32) agents. In this chapter, the expression results will reveal that
the newly designed humanized contrast agent was successfully over expressed in Luria-Bertani
broth medium, M9 minimal medium and various E.coli Cell strains using the aforementioned
expression protocol in the Chapter 2 (Section 2.3). The hProCA32 was purified following Dr.
M. Henzl’s protocol with modifications as mentioned in Dr. Shenghui Xue’s dissertation.[39,
59] This protocol, previously established for expression and purification of parvalbumin by
Henzlet.al, demonstrates that hProCA32 can be effectively isolated and purified via tagless
purification from nucleic acids coexisting in the supernatant following cell lysis. Studies were
performed to improve the product yield during the purification process by overcoming the
limitations associated with the separation of metal bound (holo) and metal free (apo) using
EGTA in the buffers. Subsequently, experimental analysis of the expression of

15

N isotope

labeled hProCA32 was also performed to improve the expression levels using M9 minimal
medium.
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4.2. Results
4.2.1. Developing the Expression and Purification of hCA32 based on previously
optimized protocol of rat ProCA32.
As discussed in section 2.3, the plasmid of hCA32 cloned into pET-22b (+) vector was
first used for small-scale expression in bacterial cells to analyze the optimal conditions for
overexpression of protein. A typical process for bacterial growth of E.coli cells has four stages
lag phase, log phase, stationary phase and death phase. The cellular growth curves in Figure 4.1
indicate that the bacterial cells of both tested E.coli strains, Bl21 (DE3) and Tuner, grew fairly
well in LB medium at 37 °C and at 25 °C after induction. Samples for SDS-PAGE analysis
were collected at various time points, before and after induction of each expression system.
SDS-PAGE gel analysis of Bl21 (DE3) cell strain indicates that there was little desired
hProCA32 expressed prior to IPTG induction for all three selected colonies. As discussed
earlier in Chapter 3, such protein expression in the absence of inducer is known as leaky
expression. Similar results were observed for the Tuner cell strain for colonies 1 and 3. For
colonies 1 and 3, bright bands around 12 kDa on SDS gel after induction suggests that the
protein was indeed expressed however the yield seemed to be relatively low (Figure 4.1 B,
right). All three colonies for BL21 (DE3) cell strain seemed to have consistent expression,
whereas Tuner cells seemed to have quite a different growth amongst the three colonies (Figure
4.1)
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Figure 4.1 Cellular growth curve for the small scale expression of hCA32 in (A)
BL21(DE3) (B) Tuner and their corresponding 15 % SDS-PAGE.
A) Small scale expression of hProCA32 transformed in to BL21 (DE3) cell strain; three
different colonies were picked and expressed in 10 mL volume of LB medium. Cellular
growth curve of the OD absorbance values at various time points of the expression and 15
% SDS PAGE analysis of the samples collected before and after induction. (B) Small scale
expression gel of three colonies of hProCA32 in Tuner cell strain in 10 mL LB medium.
Cellular growth plot at various time points during the expression and 15 % SDS-PAGE
gel of the samples before and after induction.

*Note: All the samples added to gel electrophoresis are of equal volume of the culture.
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Due to the consistency of the protein expressed after induction, BL21 (DE3) cell strain
was further used for overexpression of hProCA32. BL21 (DE3) cell strain is a mutant, derived
from BL21 that activates the T7 promoter site during the induction process[56]. In order to
optimize the expression level of hProCA32 and eliminate the expression of unwanted proteins,
another mutant of BL21, BL21 (DE3).pLysS was also used. BL21 (DE3).pLysS cell strain has a
pLysS mutation that allows the release of the T7-Lysozyme, which reduces the expression of
unwanted proteins prior to induction.
Following the successful transformation of pET-22b (+)-hProCA32 gene into BL21
(DE3) and BL21 (DE3).pLysS competent cells, the procedure implemented for the expression
of the humanized contrast agent following the method described in the Section 2.3. By the
increasing optical density of the cell culture, it can be concluded that the bacterial cells of both
competent cells grew fairly well at 37 °C before induction and at 25 °C after induction (Figure
4.2A and C). This was further evident by the increasing cloudy appearance of the medium with
time. For this particular batch of expression, flask 3 for the BL21 (DE3) cells seem to have no
change in the OD absorbance prior to IPTG induction indicating that the bacterial growth was
decreased due to possible contamination as same procedures were used for other the mediums in
other flasks. 15 % SDS-PAGE gel in Figure 4.2 B and D shows faint bands around 12 kDa
prior to induction in both competent cells indicative of leaky expression. The heavier band on
the gels corresponding to samples 3 hours after IPTG addition indicates that a significant
amount of hProCA32 protein was overexpressed. However, the density of the band was reduced
in the case of the overnight induction at low temperature. In the high amount of bacterial cell
pellets, lipids, DNA and other cellular components are expressed in large quantity along with
the of desired protein. Due to the presence of lipids and DNA, the SDS sample prepared from
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the cell pellets becomes sticky, making it difficult to solubilize in the SDS sample buffer even
after boiling and reducing its resolution. This can provide an explanation for the faint bands in
SDS gel for the overnight samples. However, the high optical densities values after the
overnight induction suggest that indeed bacterial cells were overexpressed.
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Figure 4.2 The Large scale expression of hCA32 in E.coli (A) (B) Cellular growth curve
and 15 % SDS PAGE hCA32 expressed in BL21(DE3) respectively and (C)(D) Cellular
growth curve and 15% SDS PAGE of hCA32 in Bl21(DE3).pLysS.
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Humanized contrast agent was further purified using Dr. M. Henzl’s protocol for wild-type
alpha parvalbumin, with some modifications made by Dr. Xue Shenghui, and as describe in
section 2.4. The high thermostability and water solubility of hProCA32 can be used to our
advantage for purifying hProCA32 in its pure form. Recent research has shown that high
negative surface charge has a strong correlation with an increased protein solubility.[60] Due to
high negative charge, hProCA32 is highly soluble and practically stays in the supernatant after
breaking the cell by sonication. On the other hand, nucleic acids are also highly negatively
charged and remain soluble in the supernatant. The main goal is to isolate a well-folded, pure
and functional form of this contrast agent. After breaking the cells in lysis buffer containing
protease and benzonuclease, the mixture was centrifuged to collect the supernatant. Although
hProCA32 is soluble, there are some other unwanted proteins that also soluble and remain in
supernatant after sonication as seen in the SDS-PAGE gel (lane 2) Figure 4.4 where multiple
protein bands are seen between 25 kDa to 68 kDa. Taking advantage of the thermostability of
hProCA32, the supernatant was heated in boiling water at 80-90 °C for 20 minutes to precipitate
out unwanted proteins. Figure 4.3A-B (lanes 4 and 5) demonstrates that the majority of the
unwanted proteins were eliminated out in the pellet after heating it for 20 minutes leaving
hCA32 in the supernatant. Experiments performed by previous lab members on rat ProCA32
showed the presence of high amount of DNA/RNA even after the addition of benzonuclease in
the lysis buffer[39, 61]. So, the next step is to separate the substantial concentrations of nucleic
acids that coexist along with the contrast agent (verified by UV absorbance). The supernatant
was treated with 3% streptomycin sulfate (optimized concentration), which is an antibiotic that
binds to the nucleic acids and precipitates them out. The supernatant was again heated for
another 20 minutes to get rid of any possible unwanted proteins and dialyzed in 10 mM HEPES

92

pH 8.0 prior to purification by anion exchange on a Q- column.

Figure 4.3 The purification gel of hCA32 based on Dr.M. Henzl’s protocol modified by Dr.
ShenghuiXue for rat ProCA32.
Samples taken throughout the purification of hProCA32 expressed in A) BL21 (DE3) and
B) BL21 (DE3).pLysS competent cells were applied to 15% SDS-PAGE. Each lane are
Labeled and are represented as follow: (CP) Pellet after sonication, (SP) Supernatant after
sonication, inclusion body after heating for 20 minutes, supernatant after heating for 20
minutes, inclusion body after the addition of streptomycin, Supernatant after adding
streptomycin, Cell pellet after heating it for 2nd time, supernatant after heating for the 2nd
time, supernatant after dialysis twice overnight.
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Since hProCA32 is originally a calcium binding protein, it may bind to free calcium ions
that are naturally present in the purification buffers and the presence of a mixture of calcium
bound form and calcium free form in the protein solution might affect the Gd3+ binding and
skew the results of metal binding studies. The original FPLC purification protocol for removal
of DNA/RNA from the protein solution included two rounds of FPLC, in the presence and
absence of Ca2+ and EGTA, however, large amount of protein was lost during these sets of
FPLC runs. In order to effectively remove large amounts of DNA/RNA and small nucleic acid
fragments, previous lab member Dr. Shenghui Xue simplified the purification protocol for rat
ProCA32: 1) optimizing the percent of streptomycin sulfate to precipitate DNA from the protein
solution, 2) increasing the pH of the FPLC buffers from 7.5 to 8.0 for improving the binding of
protein to the anion exchange column and 3) eliminating calcium and EGTA from the FPLC
buffer. In order to test these conditions for hProCA32, the next step is to isolate the protein
from remaining wanted cellular components and DNA/RNA fragments by anion exchange Q
column using FPLC. Q column was cleaned and charged with buffer B (10mM HEPES, 1M
NaCl pH8) followed by Buffer A (10 mM HEPES pH 8.0). At first 10 mL of dialyzed contrast
agent was injected into the FPLC system. The protein was purified following the program in
Figure 4.4, in which the injected protein first binds to the column. Subsequently, the unbound
components were washed with 5-column volume (CV) of buffer A (10 mM HEPES pH 8.0).
Slowly, buffer B (10 mM HEPES 1M NaCl pH 8.0) concentration was increased to 25 % within
next 4 CV followed by a steady increase to 35 % NaCl, salt concentration for next 2 CV.
Further, the NaCl concentration was held for 3 CV before a sharp increase to 100% NaCl
concentration to elute any possible component, protein and nucleic acids bound to the Q
column. Finally, Q- column was re-equilibrated by washing it with 100 % buffer A for 5 CV.
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Figure 4.4 FPLC salt gradient program for hCA32 purification.
Figure 4.6A and Figure 4.7 depicts a typical chromatogram from Q- column FPLC
separation of hCA32 expressed in BL21 (DE3) and BL21 (DE3).pLysS respectively. The UV
absorbance at 280 nm from FPLC detector demonstrates four to five peaks as the buffer B
(10mM HEPES, 1M NaCl pH8.0) elution increases. Fractions eluted under each peaks were
collected and tested by UV- Vis spectroscopy and 15 % SDS PAGE. Contrast agent expressed
in both competent cells, BL21 (DE3) and BL21 (DE3).pLysS seem to have similar
chromatogram. Referring to the UV spectrum of peak 1 (Figure 4.6) with high absorbance at
260 nm and absence of band in SDS PAGE it can be concluded that peak 1 is more likely to
consist of some nucleic acid fragments that were unable to bind to the column. As discussed
earlier, the presence of calcium bound protein in the purified hProCA32 may affect its Gd3+
binding. Preliminary FPLC results for hProCA32 demonstrated that it not only separated DNA
and nucleic acids fragment but holo and apo form of the contrast agents were also separated
during the anion exchange chromatography using FPLC. Anion exchange column separates
components based of the negative charge; hence a minor difference in the charge may elute the
component under separate peaks. The presence of separate peaks on the FPLC chromatogram
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suggests that the eluted protein is in different forms having varied characteristics. The holoform (calcium bound) of the contrast agent will have less total negative charge compared to the
apo-form (calcium free) of the contrast agent. Thereby, the calcium bound form elutes out first
(Peak 2) when the salt gradient is first introduced in to the program followed by the calcium
free form (Peak 3) (Figure 4.6 A and 4.7). The apo form of the contrast agents can be readily
isolated under separate peak that can be further used for its biophysical characterization and
metal binding studies. The UV-Vis spectrum in Figure 4.6C shows high absorbance at 260 nm
that are equally plateauing at 280 nm. It is evident that the desired protein is present but with
equal concentrations of nucleic acid fragments. The purification protocol for rat ProCA32,
previously established by Dr. Shenghui Xue suggests these nucleic acid fragments could be
removed by concentrating the solution several times using amicon nitrogen concentrator with
3kDa membrane. Uv-vis spectrum in Figure 4.6 and Figure 4.7 clearly shows a high
absorbance at 280 nm after concentration, indicating the elimination of nucleic acid fragments.
The Uv spectra obtained are closely related to the published spectrum of rat alpha parvalbumin
as shown in the Figure 4.5 with calcium free and calcium- loaded form.[62] For BL21 (DE3),
Peak 2, 3 and 4 shows a high-density band in SDS PAGE gel and a signature UV spectrum with
evident shoulder at 285-295 nm. The Uv spectrum of peak 2 has a spiky shoulder at 285-295 nm
indicative of the presence of holo, calcium bound form of the contrast agent and peak 4 with a
flattened shoulder at 285-295 nm consists of apo, calcium free form of the contrast agent. Since
peak 3 is not separated well, it may contain a mixture of holo and apo form. Even though the
FPLC elutes out the contrast agents under separate peaks, the final yield of the apo form of the
contrast agent is affected as only the apo form can be used for metal binding and animal
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experiment. So, further optimization of the FPLC purification process is necessary to obtain a
pure form of hProCA32.

Figure4.5 The Uv spectrum of calcium free (dashed line) and calcium loaded (solid line)
form of Parvalbumin F102W
However, in case of protein expressed in BL21 (DE3).pLysS it is evident from the FPLC
chromatogram that both peaks 2 and 3 are separated well. The SDS PAGE gel confirmed the
presence of protein in both peak 2 and 3. The distinct UV spectrum of Peak 2 with spiky
shoulder at 285-295 nm more likely corresponds to the holo form and peak 3 with flattened
shoulder indicates the presence of apo form of the contrast agent. The yield obtained for
humanized ProCA32 by using the protocol established for rat ProCA32 are relatively low
compared to the one for rat ProCA32 (40-60 mg/L). The contrast agent expressed in BL21
(DE3) had final yield of about 19.25 mg/L (apo form) and for BL21 (DE3). pLysS was 13.12
mg/L(apo form). In order to overcome this issue and increase the final yield of the metal free
form of the contrast agent, the purification protocol was further modified by two approached 1)
addition of EGTA in the purification buffers. 2) By elongating the salt gradient and holding for
a longer time when the peak 2 and 3 are eluting.
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Figure 4.6 A typical FPLC chromatogram of hProCA32 by anion exchange Q-column separation, the 15 % SDS-PAGE and
UV absorbance of each peak eluted for hProCA32 expressed in BL21 (DE3) competent cells.
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Figure 4.7 A typical FPLC chromatogram of hProCA32 by anion exchange Q-column separation, the 15 % SDS-PAGE and
UV absorbance of each peak- hProCA32 expressed in BL21(DE3).pLysS
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Another batch of hProCA32 was expressed in BL21 (DE3) and BL21 (DE3). pLysS
competent cells in LB medium following the aforementioned procedure in section 2.3. The
results for hProCA32 expressed in BL21 (DE3) are used for the illustration. The optical density
of the medium was measured at several time points, and the cell culture was induced when the
optical density reached 0.6 to 0.8. The temperature was reduced from 37°C to 25°C once the
cell culture was induced. Samples were collected before IPTG induction, and after 2 hours, 5
hours and overnight induction for SDS-PAGE analysis (Figure 4.8A). Bright protein band at
around 12 kDa on 15 % SDS-PAGE gel indicates the expression of hProCA32. It can be
concluded that the optimal condition for the expression of hProCA32 is harvesting the cell
pellet 5 hours after IPTG induction. The protein remained in the supernatant throughout the
purification process once the cells were broken by sonication as confirmed by the SDS-PAGE
(Figure 4.8 B). The purification procedures are same until the second time heating of the
supernatant. hProCA32 was dialyzed in 10 mM HEPES, 5mM EGTA at pH 8.0 for 24 hours to
entirely remove streptomycin sulfate before performing anion exchange chromatography. The
buffer was changed after 1 hour, and again after 4 hours, and then allowed to equilibrate
overnight. The next day, the protein solution was collected and centrifuged to remove possible
precipitates. The protein solution was further incubated with 10 mM of EGTA for 24 hours
prior to FPLC. As seen in the FPLC chromatogram, the majority of the protein indeed elutes out
under peak 3 (Figure 4.9A)and further supported by a bright and thick band at 12 kDa on 15 %
SDS-PAGE gel (Figure 4.9 B). The fractions eluted in peak 2, and 3 were concentrated using
an amicon nitrogen concentrator with 3kDa membrane. The Uv spectrum of peak 2 and 3 after
concentration showed high absorbance at 280 nm and low absorbance at 260 nm indicating the
removal of nucleic acid (Figure4.10).
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Figure 4.8 15 % SDS-PAGE gel of hProCA32 (A) expressed in BL21 (DE3) and (B)
purification.
(A) SDS-PAGE gel of samples before and 2 hours, 5 hours and overnight after induction
for the expression of hProCA32. (B) 15 % SDS-PAGE gel of the samples collected during
each step of purification. The protein remained in the supernatant after sonication.
Dialysis buffer prior to FPLC contained 10 mM HEPES, 5 mM EGTA at pH 8.0

Figure 4.9 A typical FPLC chromatogram of hProCA32 purified by anion exchange
chromatography and the 15 % SDS-PAGE of the fraction corresponding to the
chromatogram.
(A) FPLC chromatogram of hProCA32 incubated with 10 mM EGTA prior to the
injection in to FPLC. Majority of the protein elutes out under Peak 3. (B) 15 % SDSPAGE gel of fractions under each peak
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It is clear from the UV spectrums that proteins eluted from both the peaks are in apoform due to the presence of flattened shoulder at 285-295 nm. (Figure 4.10 A)In order to
confirm this, 5 mM of calcium solution was added to the protein solution from each peak and
UV spectrum was obtained. As expected, after the addition of calcium to the protein solution
the absorbance of the shoulder at 285-295 nm spiked up, indicating the presence of calcium
bound protein (Figure 4.10 B and C). A similar phenomenon was observed after the addition of
5 mM gadolinium to the protein solution suggesting its binding to the protein (Figure 4.10 D).
Incubating the contrast agent with 10 mM EGTA for 24 hours prior to anion exchange
chromatography indeed played a significant role in improving the yield of calcium free form of
the contrast agent. The calcium-free form of the contrast agent eluted as peak 3 can be used for
biophysical characterization and animal experiments. The final yield of the proteins eluted out
under peaks 3 was64.2 mg/2L. The final total yield of the calcium-free form of hProCA32,
using the modified protocol was 32.1 mg/L.
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Figure 4.10 UV Spectrum of the protein purified by anion exchange chromatography.
(A) The Uv spectrum of peak 2 (red) and 3 (black) after concentration, the low absorbance
of the shoulder from 285-295 nm indicates that the protein eluted under both peaks is in
apo form, calcium free form. (B) UV spectrum of peak 2: calcium free form (black) and
calcium loaded form (red) with addition of 5 mM calcium. (C) UV spectrum of peak 3:
calcium free form (black) and calcium loaded form (red) with addition of 5 mM calcium
(D) UV spectrum of peak 2: calcium free form (black), Gd3+ loaded form (red) with
addition of 5 mM gadolinium, metal loaded form (green) with addition of 5 mM
gadolinium and 5 mM calcium.
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4.2.2. Optimizing the expression and purification for 15N labeled hCA32
Nuclear magnetic resonance (NMR) spectroscopy is a valuable and reliable tool to study
the structure and function of biological molecules. Detailed analysis of structure and dynamic
properties and interaction of various compounds and biological molecules with small molecular
weight has become possible with NMR. NMR can even detect minute changes in the structural
characteristic of a biological molecule, such as ligand binding, intra-molecular interactions and
many more, by changes in chemical shift. Thus, NMR can be helpful in order to support the
data obtained by fluorescence spectroscopy for determining the dissociation constant of our
contrast agents to different metal ions like Ca2+, Zn2+ and Tb3+ etc. by monitoring various
chemical shifts. The relaxivity of our contrast agent is 10 times higher than that of the
commercially available contrast agents, and it can possibly be used for the multimodal
molecular imaging techniques. Here, NMR can be of great help to determine the dissociation
constant of our designed contrast agent to other lanthanides such as Lu3+ and Ga3+ that are
widely used for other forms of imaging modalities. Isotope labeling of organic and biological
molecules has been often used to empower and further enhance the detection ability of NMR, as
the introduction of isotopic nuclei can eliminate the coupling effects, which reduced the
complexity of the spectrum. Uniform 15 N labeling of biological molecules is widely used, as the
amount of nitrogen needed for the cellular growth can be readily controlled making the sample
preparation task easier and increases the resolution of the NMR spectra. [63]Thus, the changes
in the chemical shift of the isotope labeled hProCA32 can be monitored to attain its binding
affinity for metal ions. The primary objective of this part of work is to optimize the expression
condition of the

15

N-labeled hProCA32 and attain higher yield and higher quality protein for

NMR experiments.
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First, the contrast agent is expressed in M9 minimal medium with non- labeled NH4Cl
for preliminary experiments to investigate its growth in M9 medium, which has fewer nutrients
compared to LB medium. Since, the labeled isotopes are relatively costly; it is best to test the
optimal conditions in the non-labeled medium. The M9 minimal medium contains Na2HPO4,
KH2PO4, FeSO4, MgSO4, CaCl2, micronutrients, NaCl, thiamine, and vitamin supplements
(Detailed ingredients of M9 minimal medium are described in the Section 2.3.1.) The contrast
agent was expressed in M9 minimal and in LB medium using BL21 (DE3).pLysSE.coli cells.
The protein expressedwell in both medium (Figure 4.11 B) and further confirmed by the
western blot (Figure 4.11 A). The protein expressed in M9 was purified to attain the final yield
of 11.09 mg/L (22.18 mg/2L), which is comparable with the protein expressed in LB medium.
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Figure 4.11 Overexpression and purification of hCA32 in M9 minimal medium (A)
Western blot (B) 15 % SDS PAGE of hCA32 expressed in M9 minimal medium and LB
medium. (C) Purification of hCA32 from M9 medium (D) UV spectra of pure hCA32.
Next step is to express the contrast agent using 15N-labeled medium and to isolate high
quality, well-folded hProCA32 for NMR studies. The contrast agent was expressed in M9
minimal medium, as well as in LB medium as a control, following the protocol described in the
Methods and Materials section. The cellular growth curve in M9 minimal medium shows much
slower growth rate compared to the bacterial growth in LB medium presumably due to the lack
of nutrients in M9 medium (Figure 4.12 A) The protein was expressed at 25 °C for 6 hours
after induction, once the optical density reached 0.6. The SDS-PAGE shows the expression of
the protein with time: bright bands at 12 kDa gets heavier 2 hours after induction and 6 hours
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after induction. This indicates that reducing the temperature after inducing the cells (before
induction 37 °C to after induction 25 °C)helped in proper folding and significantly enhanced the
overexpression of the protein. This was further confirmed by western blot. Two distinct bands at
12 kDa are indeed protein bands as the antibodies used in western blot are specific to
hProCA32. As expected from the previous purification results, protein remained soluble
throughout the purification process and the unwanted proteins were precipitated during the
heating of protein solution (Figure 4.13). SDS-PAGE of the eluted fraction from anion
exchange Q column indicates that the majority of the protein remained in Peak 2 and 3 (Figure
4.14B). This was supported by western blot analysis; however, smaller amounts of protein also
eluted out in peak 1(Figure 4.14 C) as bands at 12 kDa are observed in western blot. As
mentioned earlier, western blot is a highly sensitive technique that employs antibodies specific
to the biomolecule of interest and can detect tiny amounts of the target molecule, however, it is
not as quantitative as compared to Coomassie blue staining. Coomassie blue stained-SDS
PAGE gel can detect as low as 50 ng of protein and since no protein bands for peak 1 are visible
on the SDS gel such minute loss can be ignored. Peak 2 and 3 were concentrated to remove any
possible presence of nucleic acids fragments in the solution. NMR is highly sensitive to salts;
presence tiny amounts of salts can compromise the resolution of the spectrum. The concentrated
protein samples were passed through a desalting column used to get rid of salts. The UV spectra
obtained are closely related to a typical hProCA32 spectrum, a flattened shoulder at 285-290 nm
indicates the absence of free metal ions. Although, high amount of protein was expressed, a lot
of it was lost during the purification process reducing the final yield of the protein. Either due to
the repeated centrifugation process, inefficiency of the contrast agent to bind to the Q- column
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due to insufficient cleaning of desalting column due to human error. The final yield of the 15N
labeled contrast agent was calculated to be 10.97 mg per 2 liters of expression medium.

A
Expression of

15

B

N Labeled hCA32

3.5
55
35
25

OD

15

LB Medium

2.5

10

2

1.5

15N

600

Absorbance

3

labeled

C
Flask1
Flask 2
Flask 3

1

55
35
25
15

0.5

IPTG

10

0

D
-0.5
0

100

200

300

400

500

600

55
25

Time (s)

15
10

Figure 4.12 Over expression of 15N labeled hCA32 using M9 minimal medium.
(A) Growth curve of bacterial density with time dependence: Flask1 and 2: 15N labeled M9
medium, Flask 3: LB medium (B) 15 % SDS-PAGE of 15N labeled hCA32. (C) The
western blot corresponding to the SDS-PAGE gel in (B). (D) The 15% SDS-PAGE of the
protein expressed in LB medium.
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Figure 4.13 The purifiacation of
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N labeled hCA32 expressed in M9 minimal medium.

Figure 4.14 the purification of 15N labeled hCA32 using FPLC. (A) FPLC chromatrogram
(B) 15 % SDS PAGE (C) Western Blot (D) UV spectra of the fractions eluted by FPLC Q
column.
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Figure 4.15 The UV spectra of (A) Peak 2 and (B) Peak 3 from FPLC elution after passing
them through desalting column.

4.2.3. Molecular cloning of hCA32.cys
Development of therapeutic protein drugs is the new emerging field that has been
revolutionized in the past few decades[48]. The recombinant technology and protein
engineering have been used to alter and enhance the native properties of a desired protein and
utilize it for the disease related treatments. For instance, recombinant human insulin is used to
treat diabetes mellitus, recombinant erythropoietin is used to treat anemia due chronic renal
failure or chemotherapy and many more with special targeting and diagnostic properties. [49,
64] However, these proteins are not naturally evolved for therapeutic drug application,
modifying them leads to an immune response by potential antibodies formations. Such immune
response is referred to as immunogenicity. According to the guideline by FDA, there are several
patient-specific factors and product-specific factors that influence immunogenicity that
influence immunogenicity[65]. The patient-specific factors such as genetic background of the
patient such as patient’s immunologic status, competence, sensitivity, tolerance, route, dose and
frequency of the administration differ from patient to patient and are difficult to be studied. The
product specific factors include: the origin of the protein (human or non-human sequence),
stability, solubility (aggregation), and primary structure of the protein molecule,
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glycosylation,and PEGylation. The product related factors could be optimized and monitored
while developing the protein drug.Humanization of a therapeutic protein drug is an important
method to reduce the immunogenicity. Among our previously established ProCAs, ProCA32
seemsto be the best candidate to be carried on to the next step of designing a therapeutic protein
drug, and test biophysical properties. In our approach of testing the humanized ProCA32,
PEGylation is another technique that is FDA-approved to reduce the immunogenicity effects.
As mentioned earlier in chapter1, when protein drug is conjugated with PEG, flexible and inert
PEG chains wraps up the antigenic epitopes of the drug molecule reducing the toxicity and
immunogenicity generated by foreign protein drugs and decreases the degradation caused by
proteolytic enzymes without interfering in its therapeutic properties.[50]PEG is a hydrophilic
molecule, which increases the solubility and increase in molecule weight help extend the halflife of the protein that enhances the stability with reduced renal filtration. Our previously
PEGylated versions of ProCAs demonstrated an increase in the relaxivity due to increase in the
molecular weight, changes in water properties and water-metal exchange rate due to hydrophilic
PEG. Protein modification by PEG can be done on various residues, but the most frequently
employed approach is PEG conjugation with free amine groups typically on lysine. However,
the majority of proteins sequence consists of multiple lysine residues (hProCA32 consists of 16
lysine residues as seen in Figure 4.16) and PEG specific to amine can react with any free amine
available in the sequence. This leads to the formation of multiple isomers of PEGylated-proteins
with multiple amine bearing sites being modified. Separation of such heterogeneous mixture of
PEGylated protein becomes difficult. If the modification of these therapeutic proteins does not
attain reproducibility, the regulatory FDA approval becomes complicated. In order to overcome
heterogeneous modification of our contrast agents, we followed another modification approach
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by site-specific PEG conjugation at cysteine. This approach allows selective protein
modification at a single or predetermined site with the homogenous outcome. Cysteine residues
are mainly associated with disulfide bridges and formation of secondary structures; hence,
accessible cysteine residues without any function are rarely available. A protein sequence
containing free cysteine residue, which is not involved in the disulfide bond formation and does
not play an important role in the protein functioning and activity can be used for modification.
Moreover, a cysteine residue can be introduced in the protein sequence either replacing a nonessential amino acids from the protein sequence or insertion at a desirable position can be easily
attained by site-directed mutagenesis. In case of hProCA32, a cysteine residue was inserted at
the N-terminus to allowsite-specific conjugation of a single PEG at thiol group on cysteine
using maleimide-PEG. Forward and reverse primers were designed, as shown in the Figure
4.17A; DNA gel electrophoresis results in (Figure 4.17 B) shows a band at
6000bpcorresponding to expected template DNA. This indicates that the molecular cloning
experiment was successful. The plasmid construct was further confirmed by getting it
commercially sequenced from GENWIZ. The DNA sequence obtained from the sequencing was
analyzed and aligned by Blast and Clustalw. The DNA and protein sequence alignment in
Figure 4.18 shows the desired mutation at C-terminal of hProCA32 was successfully inserted
into the plasmid.

112

Figure 4.16 Possible Lysine (Cyan) and Cysteine (Beige) PEGylationsites on hProCA32.
Xray crystalized structure obtained from pdb file 1RK9 and modified using USCF
Chimera S56D, D101E and F103W
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Figure 4.17 Molecular cloning of hCA32.cys by PCR (A) Forward and Reverse Primer
design for site directed mutagenesis of hCA32 (B) DNA gel electrophoresis of the plasmid
obtained after PCR
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Figure 4.18 DNA and protein sequence alignment of mutated variant hCA32.cys with
hCA32

4.2.4. Expression and purification of hProCA32.cys
The next step is to express and purify the newly cloned hProCA32.cys, and to
study its biophysical properties after peglytion. The mutated contrast agent hProCA32.cys was
purified using the aforementioned protocol described in section 2.12.2. The apparent increase in
the optical density of the cell culture suggests that the bacterial cells containing the genetic
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encoding of hCA32.cys grew fairly well. A faint band at 12 kDa in 15 % SDS-PAGE gel
depicts some amount of contract agent was expressed prior to IPTG induction indicating the
occurence of leaky expression (Figure 4. 19B). hProCA32.cys includes of a cysteine at its Cterminal which introduces the capability to form a disulfide bond thus forming a dimer.
Surprisingly, most of the protein remained as a monomer. The OD absorbance plot and bright
band at 12 kDa in SDS-PAGE indicates that a high amount of protein has been expressed after
induction at 25 °C temperature.
The protein was isolated using the protocol implemented for the purification of
hProCA32 as described in section 2.4. Similar to hProCA32, the mutated variant hProCA32.cys
is expected to have high thermostability and solubility. After harvesting, the bacterial pellet was
solubilized in 10 mM HEPES at pH 7.3 containing 1 μL benconuclease, PMSF and 5 mM DTT
(Dithiothreitol, a reducing agent to keep the SH- group in reduced state).As expected, the
protein remained in the supernatant after the bacterial cells were broken by sonication. As seen
in Figure 4.20, most of the unwanted proteins vanished when the sonicated supernatant was
boiled at 80-90 °C for about 20 minutes. Streptomycin precipitated out most of the coexisting
nucleic acid. In order to analyze the in solution composition of the protein, SDS- PAGE
samples were kept in non-reducing condition. After heating the supernatant second time some
of the protein was visible as dimer, which is clearly observed in the purification gel (Figure
4.20B) at about 24 kDa The band intensity in SDS-PAGE 12 kDa was enhanced by the dialysis
of the contrast agent in 10 mM HEPES and 5 mM DTT at pH 8.0, most of the protein remained
in its monomer form throughout purification due to the presence of DTT in the buffers.
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Figure 4.19 Overexpression of hCA32.cys in E.coli (A) Cellular growth curve (B) 15%
SDS-PAGE of hCA32.cys expressed in BL21 (DE3).pLysS and LB medium.

Figure 4.20 SDS-APGE of purification of hCA32.cys where no reducing agent was added
to the sample buffer. However, the protein solution contained 5 mM DTT as a reducing
agent.
The anion exchange chromatography eluted five different peaks, and the SDS gel
electrophoresis clearly indicated that most of the protein was present in either peak 2 or 3
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(Figure 4.21D). The high UV absorbance (peak1) in the binding step of FPLC clearly indicates
that the desired protein is not binding to the column and eluting out prior to the introduction of
the salt gradient in the FPLC program. This can be further confirmed by 15 % SDS-PAGE gel
of the fraction eluted under peak 1, where a clear band is observed at 12 kDa. This could be due
to many possible reasons but most commonly due to overloading of the sample as the presence
of significant amount of protein in the solution may exceed the column capacity. High salt
concentration present along with the contrast agent prior to the FPLC injection can reduce the
binding efficiency of the column and subsequently reduces its capacity. Thus, some of the
protein remained unbound to the column and eluted out first in peak 1. In order to check this
possibility, the eluted fractions were diluted with water and re-chromatographed. The rechromatographed spectrum looked similar to the first run except with low UV absorbance
(Figure 4.21B), suggesting that the presence of high salt in the protein solution indeed hindered
the column binding process.
The presence of three separate peaks suggests that the eluted protein with different
forms may have varied characteristics. Inferring the UV spectrums of each peak, it can be
implemented that the majority of the protein eluted out in peak 2 and 3. The UV spectrum of the
fractions eluted under all of the five peaks has absorbance at 260 nm that equally plateaus at
280 nm. UV spectrum in Figure 4.22B clearly shows a high absorbance at 280 indicating the
presence of protein.
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Figure 4.21 (A) Typical FPCL chromatogram of hCA32.cys purified by Q- column
separation, (B) The spectrum of re-chromatography of peak 1 from A(C) the UV
absorbance and (D) 15 % SDS-APGE gel of each fraction.
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Figure 4.22 UV absorbance of concentrated hCA32.cys
The structural characterization of purified hCA32.cys by UV spectroscopy demonstrated
a sharp peak at about 285-290 nm that is consistent with the hCA32 purification results further
confirming the presence of high quality protein. Although a relatively high peak at 260 nm is
suggesting possible presence of nucleic acid, it can be removed by concentrating the protein
using a 3kDa membrane. Fractions eluted under peak 2 and Peak 3 from FPLC were
concentrated and according to UV absorbance and ε280= 7200 M -1cm-1, the total yield was
26.64 mg/L.
4.2.5. Purification of rat ProCa32 expressed using fermenter
A higher dosage of protein is required to study the imaging properties of ProCAs in
large animals and humans as compared to mice. The large-scale production of our designed
ProCAs is another stumbling block for commercialization. Although ProCA32 is a desired
candidate, it must have reproducible quality and high efficiency during industrial production.
The expression and purification process must be readily scalable with reduced production cost.
For this purpose, 12 liters of ProCA32 was expressed in a bioreactor with well-established pH,
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temperature, airflow and oxygen levels (Protocol in Dr. Shengui Xue’s dissertation) [39]. The
cell pellet obtained was purified to ensure the protein quality and its relaxation properties.
The cell pellet was homogenized in the lysis buffer and sonicated to break the bacterial
cells. ProCA32 is highly soluble hence after breaking the cells by sonication, and the initial step
is to separate the protein from insoluble cellular components by centrifugation. The 15 % SDS –
PAGE gel (Figure 4.23) shows that most of the insoluble cellular components were removed in
the pellet and ProCA32 remained soluble in the supernatant. ProCA32 has a unique property of
maintaining its stable conformation when exposed to higher temperature, thermo stable. Hence,
heating the solution would be an efficient and suitable way for industrial production to remove
the unwanted proteins that are not stable at high temperature. The solution was heated at 90°C
for 20 minutes and centrifuged at 7000 rpm to precipitate out the majority of non-heat stable
proteins in the pellet. As discussed earlier, the proceeding step of purification is to precipitate
out nucleic acid by treating the supernatant with, streptomycin sulfate. Heating the supernatant
at 90 °C for second time assured the removal of any remaining unwanted proteins. The protein
was then isolated from remaining nucleic acid fragments and impurities by FPLC- anion
exchange column with a salt gradient program. The nucleic acids have higher negative charge
compared to protein; hence nucleic acid remains bound to the column strongly. As the percent
salt concentration increases the protein that is bound the Q- column is competed by the salts
present in the buffer and elutes out first. The FPLC chromatogram demonstrates that the
injected protein solution eluted out in 5 different peaks (Figure 4.20). Each fragment was
analyzed by 15 % SDS-PAGE as shown in the Figure 4.25. As the salt concentration (Buffer B10 mM HEPES, 1M NaCl pH 8.0) increased to 25 % the protein eluted under Peak 2 and 3. The
first step is the binding of the protein to the column in the presence of no salt buffer A (10 mM
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HEPES pH8.0). Slight increase in UV absorbance at low salt concentration of FPLC run
suggests that some of the protein remained unbound to the column and eluted out under peak 1,
which was further confirmed by the presence of a band around 12 kDa revealed in 15 % SDSPAGE and by UV-Vis spectroscopy. This may have occurred due to the presence of high
concentration of nucleic acids along with the contrast agent reducing the binding efficiency of
the column.

Figure 4.23The purification gel of ProCA32 based on the purification method from
Shenghui Xue’s dissertation.
The 15 % SDS-PAGE gel shows all the samples taken throughout the purification process
of the bacterial expression of the protein at 12 L scale.
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Figure 4.24 FPLC Spectrum of anion exchange Q- column.
A clear and bright band at 12 kDa in 15 % SDS-PAGE gel indicates successful isolation of ProCA32 in fractions under the
highlighted red and green box. The two distinct peaks 2 and 3 represents holo and apo form of the ProCA32, respectively.
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Figure 4.25 UV-Vis Spectra indicates a successful separation of ProCA32 in 10 mM HEPES
pH 7.2.
The fractions eluted under each peak were analyzed by 15 % SDS-PAGE and further
confirmed by the UV-Vis spectroscopy. The gel indicates the presence of Protein in Peak 2 and
3. The elution under peak 1 shows a light band at 12 kDa suggesting that some of the protein
remained unbound to the column. The UV-Vis spectrum of peaks 1, 2 and were identical with a
signature shoulder at 285-295 nm that is unique to ProCA32. The presence of this shoulder
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4.3. Conclusions
Development of a protein based contrast MRI contrast agent is a challenging field. In
order to design a protein based contrast agent, selection of scaffold protein prior to building a
Gd3+ binding pocket is extremely important. For the third generation of ProCA, we have selected
parvalbumin (PV) as a scaffold protein, which is highly stable, soluble, and tolerant to mutation.
Moreover, PV is naturally a calcium binding protein and hence is capable of binding lanthanides.
PV has no reported interactions with other proteins or peptides. Previously, a series of the third
generation of ProCA (ProCA3) were designed (by Dr. Shenghui Xue), out of which ProCA32
variant showed a significantly high relaxivity both in vitro and in vivo. In developing a protein
based contrast agent next step would be to humanize it with the goal of reducing the
immunogenicity effects in humans. We have designed ProCA32 using the human sequence of
PV with necessary mutations.
In this chapter, the expression of humanized ProCA32 (hCA32) has been optimized using
various E.coli cell strains. The protein seems to express well in BL21(DE3).pLyS

and

BL21(DE3) competent cells. Further, the protein was isolated from unwanted protein and nucleic
acids by heating it twice. Along with the contrast agent, nucleic acids are highly stable at high
temperature as well; streptomycin sulfate was used to precipitate nucleic acid from the solution.
Although the majority of nucleic acids were removed, the remaining nucleic acid fragments were
further removed by anion exchange chromatography. Since hProCA32 is originally a calcium
binding protein, it may bind to free calcium ions that are naturally present in the purification
buffers. The anion exchange column separates components based on the negative charge; hence a
minor difference in the charge may elute the component under different peaks. The holo form
(calcium bound form)of the contrast agent with less total negative elutes out first (Peak 2) when
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the salt gradient is first introduced in to the program followed by the apo form (calcium free
form) Peak 3 which was confirmed by the UV spectrums. High quality apo form of the contrast
agent was isolated using both competent cell types, but with relatively low yield (13-19 mg/L)
compared to rat ProCA32 (50-70 mg/L). In order to improve the yield of the apo form of the
protein the purification process was optimized with the addition of 5mM EGTA in the dialysis
buffer and incubating the protein with 10 mM EGTA for 24 hours prior to the anion exchange
chromatography. The majority of the apo form of the protein was extracted from peak 3, with the
final yield of 32.1 mg/L.
The expression and purification of 15N labeled contrast agent were also optimized where
the contrast agent was expressed in M9 minimal medium. Large amounts of protein were
expressed; however a lot was lost during the purification process. The purification process must
be further optimized to attain high yield. In our approach to reduce the immunogenicity effects,
one of the techniques applied is a conjugation of the contrast agent with PEG. To obtain
homogeneous and site-specific PEGylation, a cysteine residue was inserted at the C-terminal of
our hProCA32. The purification of the mutated variant, hProCA32.cys was also optimized under
reduced conditions with a final yield of 26 mg/L. The cysteine PEGylation of hProCA32.cys will
be shown in chapter 5. Furthermore, the purification of rat ProCA32 expressed using large-scale
expression system; fermentation yielded 4 mM of 4 ml of pure proteins per 5 g of the wet pellet.
In summary, the humanized ProCA32 and its mutant has been successfully optimized to
over express and purify under the conditions mentions earlier (Chapter 2) with high yield. The
purified contrast agent, hProCA32 is further used for characterizing it structural and biophysical
properties in the following chapter.
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5. RELAXIVITY, METAL BINDING, SELECTIVITY AND STABILITY
OFENGINEERED HPROCA32
5.1. Introduction
The primary focus of this chapter is to characterize the biophysical properties of the
newly designed hProCA32 such as metal binding and selectivity, relaxivity and PEGylation. The
criteria for an ideal contrast agent are high relaxivity, in vivo stability and high gadolinium
binding affinity, as well as selectivity for Gd3+ over other physiological metals. If the binding
affinity of the contrast agent for gadolinium is not strong enough, the metal can be released from
the binding pocket, generating toxic effects which are caused by the accumulations of free
gadolinium leading to nephrogenic systemic fibrosis (NSF) or nephrogenic systemic dermopathy
(NSD) [28]. Since gadolinium is a trivalent lanthanide that has similar ionic radius to divalent
calcium, it can easily bind to calcium binding pockets on protein molecules as Gd3+ and Ca2+
have similar coordination with a stronger preference for oxygen as a ligand. Binding of calcium
to the contrast agent may hinder the imaging process in vivo and on the contrary, if free
gadolinium binds to other physiological calcium binding proteins, it can disrupt the dynamic
biological functioning which required calcium [66]. Theoretically, the hProCA32 should have
similar relaxivity to rat ProCA32 and higher compared to the commercially available small
molecule contrast agents. Another important characteristic of a contrast agent is having an intact
structure and stability against proteolytic cleavage by proteases under physiological conditions.
Furthermore, to reduce the immunogenicity of the protein based contrast agent, the hProCA32
has been modified with a long polymer chain of PEG by conjugation.
The main objective of this chapter is to investigate the binding of physiological metals
such as Ca2+ and Zn2+ and lanthanides such as Tb3+and Gd3+ to humanized ProCA32. Relaxivity

127

measurements and serum stability of hCA32 are performed to further test its suitability as a
contrast agent. Various lengths of PEG are conjugated to test its effect on physical characteristics
of hProCA32.
5.2. Results
5.2.1. Site specific Lysine and Cysteine PEGylation
Addition of polyethylene glycol chains with various lengths (also known as PEGylation)
has been frequently used in development of therapeutic protein drugs as a method to decrease the
immunogenicity and renal excretion, improve the drug delivery, in vivo solubility, stability and
biocompatibility [67]. Protein conjugated with PEG improves the biological functioning as it can
increase the size of the protein-drug, which in turn reduces renal clearance (filtration by kidney)
and subsequent increase in the circulation half-life and eventually, prolonging the blood retention
and improving the drug delivery [50, 68]. Long hydrophilic chains of PEG (CH) also envelops
the drug-protein and shields it from the antigenic epitope and helps in reducing the immunogenic
response generated by the introduction of foreign biomolecules and improves the solubility.
However, if the length of PEG is not optimized, it may mask the functioning site and affect the
therapeutic and biological functioning of the protein drug. As discussed earlier in Chapter 4, our
lab has performed PEGylation on first generation of ProCAs which demonstrated significant
improvement in in vivo MR imaging and r1 and r2 relaxivities along with improved
biocompatibility properties including dose efficiency, solubility and blood retention and
decreased immunogenicity. [38] Up to date, lysine PEGylated of ProCAs has been used for the
animal studies; however, lysine PEGylation generates heterogeneous solution due to the presence
of multiple lysine residues in our contrast agents. In order to study and optimize the specific
PEGylating sites and assess the homogeneity and its effects on the relative metal binding sites,

128

we have designed a mutant containing cysteine at the C- terminal of the protein. The molecular
cloning, overexpression and purification of this mutant (hProCA32.cys) are described in chapter
4. In this section, the PEGylation of hProCA32.cys with various lengths of PEG reagents has
been optimized to achieve the highest quantity of PEGylated reagent.
Following purification, 500 µL of protein was mixed with 1 to 10 volumetric ratio of
TCEP in the presence of nitrogen gas. The mixture was allowed to react for 20 minutes followed
by removal of TCEP by concentrating the protein using a 3kD filter membrane (Amicon).
Meimide-PEG reagent was added with 1:5 molar ratios, and then the PEGylated protein was
separated from free PEG reagent by concentrator. The protein was PEGylated with 0.710 kDa,
1.24 kDa, 2 kDa and 10 kDa PEG chains. PEGylated contrast agents, stained (2kDa and 10 kDa)
by barium-iodine staining followed by SDS-PAGE gel, confirmed that the protein has been
successfully PEGylated (Figure 5.1). Each PEGylated protein was further analyzed by the
MALDI mass spectroscopy (Figure 5.2). An apparent difference can be observed in the
molecular mass of protein before (Figure 5.2 A) and after PEGylation (Figure 5.2 B, D and E).
The MALDI spectrum of hProCA32.cys conjugated with 2 kDa PEG.cys reagent has a broad
range of peaks centered at 14.41 kDa due to the polydispersivity of PEG reagent.[67] Each
polyethylene glycol (O-CH2 –CH2) unit has a molecular weight of 44.05 Da (g/mol). The
difference between each peak in MALDI spectrum is about 44-45 Da corresponding to the
different lengths of PEG. Such difference indicates that the PEG reagent consists of a
heterogeneous mixture of various lengths of PEG units. The methionine group in hProCA32 is
often cleaved which explains the reduced molecular mass peak of the hProCA32 conjugated with
1.24 kDa and 0.710 kDa PEG reagents (Figure 5.2 D and Figure 5.2 E). The next step is to
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measure the relaxivity, metal binding and metal selectivity to conclude which length of PEG is
suitable for in vivo studies.
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Figure 5.1Iodine stained and coomassie blue stained gels depicting the PEGylation of hCA32.cys
((A) The iodine stain and SDS-PAGE gel of hProCA32.cys, PEGylated with 10 kDa PEG. A 10kDa increase in the molecular
size is clearly observed by the gels. Both staining suggest that the protein has been PEGylated with more than 90 % efficiency.
(B) The iodine stain and SDS-PAGE gel of hCA32.cys, PEGylated with 2 kDA PEG. A 2kDa increase in the molecular size is
clearly seen by the gels. In SDS-PAGE, a light density band is visible at 12kDa suggesting that some protein remained unPEGylated.
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Figure 5.2 the mass spectra of hProCA32.cys before and after PEGylation.
(A) MALDI spectrum of hProCA32.cys before PEGylation showing the molecular mass of
12.4 kDa. (B) hProCA32 after conjugation with 2 kDa PEG and peak centered at 14.43 kDa
and (C) The zoomed in region of spectrum in B. Polydispersed peaks of mal.PEG reagent
with 44.05 Da (one PEG units) difference between each peak is causing such peak
broadening. (D) Mass spectrum with a peak at 13.34 kDa corresponding to hProCA32
conjugated with 1.24 kDa PEG and (E) Mass spectrum with a peak at 12.82 kDa
corresponding to hProCA32 conjugated with 0.710 kDa PEG
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5.2.2. Relaxivity measurements
The relaxivity of hCA32 was measured in 10 mM HEPES at pH 7.2, 37 °C. The Gd3+
concentration was fixed at 100 µM and various hProCA32 concentrations were added from 0 to
200 µM. T1 and T2 of water for each sample were measured. It has been proposed that increasing
the metal binding site shortens the transverse and longitudinal relaxation times and hence
reducing the relaxivity. As seen in Figure 5.3, the relaxation times, T1 and T2 shorten as the ratio
of protein to gadolinium increases until the concentration of protein reaches a 1:2 ratio with
gadolinium. Keeping the gadolinium concentration fixed at 100 μM, the relaxation times
decrease to the lowest at 50 μM of hProCA32, indicating 1:2 binding. The average relaxivity
calculated at 1:2 ratio is indeed the highest, r1 = 27 mM

-1

s

-1

and r2 = 36 mM

-1

s

-1

and is

comparable with the rat ProCA32 (Figure 5.4). The relaxivity value rapidly drops at the
concentrations higher than 1:2 ratios (Figure 5.4). The reason behind this phenomenon is unclear
and still needs to be explored. hProCA32 is known to have heterogeneous gadolinium binding
sites. The S56D mutation in hProCA32 (The first residue methionine excluded) is identical to the
S55D mutation in the wild-type α and β parvalbumin (The First residue methionine included)
studied by Henzl et al[69]. The calcium-binding studies performed by Henzl reported the
macroscopic stepwise binding constant for S55D mutants examined in HEPES- buffered saline at
pH 7.4 at 25 °C where (CD site) K1 = 2.5(0.2) x 108 and (EF site) K2 = 6.2 (0.2) x107[69].
Considering the similarities between the ionic radii and coordination of gadolinium and calcium
it can be assumed that the gadolinium will exhibit similar trend in the binding affinities for each
site. If we assume that the CD site has a stronger gadolinium binding affinity and EF site has a
weaker gadolinium binding affinity, the overall average binding affinity still remains high. The
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increase in relaxation times at concentrations below 50 μM of the protein, which is relatively
lower than the gadolinium concentration, is mostly due to the saturation of both strong and weak
metal binding sites. Once the protein concentration reaches above 50 μM, the gadolinium can
selectively bind to the strong metal binding site leaving the weak metal binding site unoccupied.
Hence, an increase in protein concentration causes a decrease in the amount of metal bound and
thus reducing the relaxivity. Furthermore, the relaxivity studies of hProCA32 linked with
cysteine PEG needs to be analyzed as a future direction.

Figure 5.3 The measurement of T1 and T2 relaxation time for hProCA32 with 100 μM Gd 3+
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Figure 5.4 The relaxivity measurements of hCA32 compared with rat ProCA32 expressed
by fermentation.
(A) r1and(B) r2relaxivities of rat ProCA32 and hProCA32 in buffer containing 10 mM
HEPES, pH 7.2 and 100 μM of Gd3+ at 37 °C.

5.2.3. Equilibrium Calcium titration
Humanized ProCA32 is originally a calcium-binding protein, α-parvalbumin with two
metal binding pockets. α-Parvalbumin is reported to have a strong calcium binding (Kd of
around 10-9 M) [70]. Although some mutations were performed on PV to improve its Gd3+
binding affinity, the possibility of binding to calcium remains highly likely. Hence, the calcium
binding affinity of hProCA32 must be tested. However, it is difficult to control the free metal ion
concentrations and measure strong affinity using direct fluorescence titration. To overcome these
limitations, the Yang lab has developed metal chelator buffer system, where the free metals in
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the system are tightly controlled by the high concentration of chelator, EGTA in this case. The
total Ca2+concentration in each titration point is tightly controlled, and the exact total
Ca2+concentrations were titrated into the system. For example, if 100 μM of total Ca2+is titrated
in the system, it generates 7.51 x10-9 M free Ca2+ in the system according to Equation 5-1. The
experiment was performed following the procedure in section 2.11in which 1 μM of hProCA32
was added to buffer containing 5 mM EGTA, 50 mM HEPES, and 150 mM NaCl, pH 7.2 and
calcium was titrated in increments, while monitoring the fluorescence with excitation at 280 nm
and emission range of 300-400 nm. Calcium was titrated until the chelator present in the system
(EGTA) was saturated; hence approximately 5 mM of total calcium was titrated into the system.
The fluorescence changes of tryptophan are monitored to probe the changes caused by binding of
calcium. Fluorescence intensities were graphed versus emission wavelength (Figure 5.5 A) and
the maximum intensities at 311-315 nm were fitted by Hill equation (Equation 5-2) to obtain the
Kd (Figure 5.5 B). The binding affinity of hProCA32 to Ca2+ was thus experimentally measured
to be 1.35 × 10-8 M, which falls in the reasonable range and relatively comparable to the one for
rat ProCA32.

[𝑪𝒂𝟐+ ]𝒇𝒓𝒆𝒆 = 𝑲𝒅𝑪𝒂−𝑬𝑮𝑻𝑨 ×
𝒇=

[𝑪𝒂𝟐+ ]𝒇𝒓𝒆𝒆

𝒏

𝑲𝒅𝒄𝒂−𝑬𝑮𝑻𝑨 𝒏 +[𝑪𝒂𝟐+ ]𝒇𝒓𝒆𝒆

[𝑪𝒂−𝑬𝑮𝑻𝑨]
[𝑬𝑮𝑻𝑨]𝒇𝒓𝒆𝒆

𝒏

Equation 5-1

Equation 5-2
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Figure 5.5 Determining the metal binding affinity of hProCA32 using metal chelator buffer
system.
(A) The fluorescence spectra of hProCA32-Ca2+ titration using metal chelator buffer
system with excitation at 280 nm and emission range of 300-400 nm. (B) The fitted curve of
the maximum intensity at 311 nm with a dissociation constant of 1.35 × 10-8 M using hill
equation (Equation 5-2).
5.2.4. Determining metal biding affinity of hProCA32 using Tb3+ EGTA/DTPA buffer
system
Lanthanides tend to bind to EF-hand calcium-binding proteins with high affinity.
Terbium (Tb3+)is a trivalent lanthanide possessing similar ionic radius and coordination as
calcium. Due to its unique fluorescence properties, Tb3+ is frequently used as a probe in
fluorescence spectroscopy to study the intrinsic metal binding properties of biomolecules. In
FRET, accessible tryptophan upon excitation transfers energy to terbium and generates
fluorescence signal. Tryptophan is excited at a wavelength of 282 nm, which emits at 340 nm; a
wavelength range where terbium can absorb energy. Once the terbium absorbs energy at 340 nm,
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it emits the energy between 545 nm and 595 nm. Our previously developed rat ProCA32 has
been reported to have a strong binding affinity for Tb3+ of about 10-22 M. The humanized
ProCA32 must have a similar binding affinity to Tb3+. However, it is extremely difficult to
accurately measure the binding affinity in such small range using fluorescence. Fluorescence
titration has limited sensitivity and the free metal in the solution can generate its own
fluorescence. In order to overcome these limitations, metal chelator buffer system can be used to
control the free metal in the system. The dissociation constants for chelators such as EGTA and
DTPA to Tb3+ are obtained from the National Institute of Standards and Technology (NIST).
Changes in Trp fluorescence can be monitored to analyze the metal binding affinities at
extremely low concentrations of free Tb3+. The Tryptophan (Trp) residue present near the
binding site can be excited at 280 nm, which has an emission at 315 nm. This can further excite
the Tb3+ that is bound to the protein, and the fluorescence emission can be observed at 545 nm.
This system contains 50 mM HEPES, 150 mM NaCl, 30 μM hProCA32, 5mM EGTA or
DTPA and 0.1 μL Rhod-5N, pH7.2. EGTA and DTPA have a Kdto Tb3+of 10-18 M and 9.55 ×
10-22 M, respectively. The system contains about 170 times higher concentration of the chelator
than that of the protein; therefore the majority of the protein should be in its apo form (metal free
form). Tb-EGTA system can create a buffer range from 10-18 to 10-9 M of free Tb3+. EGTA is a
weak chelator as compared to DTPA and can be used Tb-DTPA can generate a buffer range
between 10-22 and 10-18 M of free Tb3+. The Kd of the protein is first tested in the weaker buffer
range using EGTA followed by, the stronger buffer range using DTPA. As a weak metal binding
indicator, the fluorescence of Rhod-5N can increase when free [Tb3+] is higher than 10-6 M. Tb3+
itself has its own fluorescence, thus as a background control, a parallel experiment was
performed where 5 mM EGTA or DTPA, 50 mM HEPES, 150 mM NaCl pH 7.2 were used as a
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buffer and Tb3+ was titrated to the system.
Figure 5.6 A and Figure 5.7 B are the control experiments with Buffer- 5mM EGTA and
buffer- 5mM DTPA, respectively. Various volumes of Tb 3+ were titrated into the system. B and
D are the titration plots with 30 µM of hProCA32 into buffer-EGTA and Buffer-DTPA,
respectively with fluorescence intensity subtracted from the background Tb3+ from the control
experiment. Various volumes of Tb

3+

were titrated in to the system, as the [Tb3+] increased the

fluorescence intensity at 545 nm, which is an indication of Tb3+ binding to hProCa32.
The increase in fluorescence intensities at 545 nm in Figure 5.6 and Figure 5.7
demonstrates that energy transfer between Tb3+ and hProCA32 occurred in both Tb-EGTA and
Tb-DTPA buffer systems. Therefore, hProCA32 can bind to Tb3+ ata low concentration range of
10-18 to 10-22 M. The fluorescence intensities at 545 nm were plotted using hill curve fitting, and
binding affinity constants were calculated using Hill equation. hProCA32 has the KdhCA32,Tb of
-22
M using Tb-DTPA
1.41x10-18 M using Tb-EGTA buffer system and KdhCA32,Tb of 7.79 x 10

buffer system. These dissociation constants are comparable to the ones for rat ProCA32.
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Figure 5.6 Fluorescence spectra of hProCA32 binding with Tb3+ using metal chelator buffer
system.
(A)The EGTA buffer system contained 50 mM HEPES, 150 mM NaCl at pH7.2, and 5 mM
EGTA was used a control where(B) contained 50 mM HEPES, 150 mM NaCl at pH7.2, 5
mM EGTA and 30 μM hProCA32. As the Tb 3+ was titrated in to the system, the
fluorescence intensity at 545 increased due to the binding of protein to the free metal. Once
the total metal concentration is higher than the DTPA, low affinity dye Rhod-5N binds to
the remaining metal causing an increase in fluorescence intensity at 575 nm, which
indicates that the system has reached its saturation point. The curve has fluorescence
intensities subtracted with the backgroundsignal generated by Tb3+ itself. The curve fitting
of these intensities at 545 were done using Hillequation. (C) The actual fluorescence
intensities plotted to monitor the dynamic range and (D) the normalized fluorescence
intensities to obtain the binding affinities.
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Figure 5.7 Determining Tb 3+binding affinity of hProCA32 using Tb3+-EGTA / DTPA
system
(A) The EGTA buffer system contains 50 mM HEPES, 150 mM NaCl at pH7.2, 5 mM
EGTA and 30 μM hProCA32. (C) Saturation test where the maximum fluorescence
intensity peak corresponds to Rhod-5N-Tb3+ complex where the minimum fluorescence
intensity peaks corresponds to Rhod-5N (λEx= 551 nm, λEm= 576 nm).
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5.2.5. Determining the affinity of hProCA32 to Gd3+ using various fluorescence
assays
The binding affinity of hCA32-Gd3+ was first determined using fluorescent dye, Fluo-5N
pentapotasium salt, which is a weak calcium indicator. The binding affinity of Fluo-5N to Gd3+,
3.8 ± 0.2 ×10

-12

has been previously determined by Yang’s lab using Fluo-5N-NTA buffer

system [29]. The experiment was performed using the lower metal and dye concentrations, 1 μM
Fluo-5N and 1 μM Gd3+, in 10 mM HEPES at pH 7.2, and the initial fluorescence intensity was
measured between 500 nm to 600 nm with excitation at 488 nm. Using this method, various
concentrations of gadolinium were titrated gradually causing a decrease in fluorescence intensity
as the saturation point approached. This decrease is caused since the contrast agent competes the
gadolinium out from the dye and hProCA32-Gd3+ complex does not have a fluorescence of its
own. This experiment was performed in triplicate. Fluorescence intensity versus wavelength is
shown in Figure 5.8A. The fitted curve at maxima 519 nm displaying the Kapp is shown in
Figure 5.8 B. The Kd for hProCA32-Gd3+ was calculated using Equation 5-3 (derivation shown
in Section 2.11). The binding affinity of hProCA32 and Gd3+ using the Fluo-5N competition
assay is 1.08 ×10-11 M, which is lower than the Ca2+ binding constant of hProCA32 (1.35 x 10-8
M).

𝑲𝒅𝟐 = 𝑲𝒂𝒑𝒑 𝑲

𝑲𝒅𝟏

𝒅𝟏 +[𝑭𝒍𝒖𝒐−𝟓𝑵]𝑻𝒐𝒕𝒂𝒍

Equation 5-3

Although this method is a reliable way to determine the binding affinity of our contrast
agent, it has its own limitations, as Fluo-5N is a weak calcium indicator and its affinity for Gd3+
is in a lower range to begin with. Yang lab has developed another indirect technique utilizing the
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förster resonance energy transfer (FRET) property of Tb3+ and tryptophan residue present in the
protein. When excited at 280 nm, tryptophan residue present in hProProCA32 has an emission at
345 nm. This energy released by the tryptophan (donor) is transferred to the Tb3+ (acceptor) that
is present within the Förster’s distance at about 10 Å. Thus, Tb3+ is excited at 315 nm and emits
at 545 nm. In the competition assay, the protein was preloaded with Tb3+ and Gd3+ was titrated
to the protein-Tb3+ complex. Gd3+ competes the Tb3+ out of the metal binding pocket, and since
there is no energy transfer between Gd3+ and tryptophan, the emission at 545 nm decreases as
Tb3+ is competed out.

Figure 5.8 Determining binding affinity of hProCA32 for Gadolinium using Fluo-5N
competition assay
(A) Competition assay with 1 μM Fluo-5N and 1 μM gadolinium in 10 mM HEPES at pH
7.2 with hProCA32 titrated to determine the Kd (excitation at 488 nm, emission 500- 600
nm). (B) Fitted curve at maximum intensity of 519 nm displaying the Kapp=2.84 μM and
calculated Kd of 1.08 ×10-11 M.

145

Now that it is confirmed that our contrast agent is capable of binding to gadolinium and
has a strong binding affinity for Tb3+, as determined by metal chelator buffer system, the next
step is to determine the gadolinium binding affinity with applying this information in designing
the experiment. Since Gd3+ does not fluoresce upon excitation, we use an indirect assay.
Gadolinium binding affinity for hProCA32 was determined using competition experiments with
Tb3+, where Gd3+ competes with Tb3+ that is bound to hProCA32 causing a decrease in
fluorescence intensity. Ten micromolar of hProCA32 and 20 μM of TbCl3 in 50 mM HEPES,
150 mM NaCl, pH 7.2 were incubated with different Gd3+ concentrations ranging from 0 to 1000
μM at room temperature overnight. The Tb3+ fluorescence energy transfer signal changes were
measured by excitation at 280 nm and emission at 545 nm. As shown in Figure 5.9 A, free Gd3+
indeed competes Tb

3+

out of the binding pockets of hProCA32 indicating a decrease in

fluorescence intensity upon addition of Gd3+ with an apparent Kd (Kapp) of 8.3 μM. The
Gd3+binding affinity of hProCA32 calculated using one to one binding equation was 2.83 x 10-22
M (Equation 2-7). However, Kd using this technique is highly sensitive to the values used for Kd
of hProCA32-Tb3+, which in turn is highly dependent on the dissociation constants of the
chelator-Tb3+. The binding affinity of hProCA32 falls in the similar range as compared to rat
ProCA32 suggesting that despite of 20 % difference in the protein sequence, hProCA32 has
similar physical characteristics as ProCA32 as a contrast agent.
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Figure 5.9 Determining the Gd3+ binding affinity of hProCA32 using competition assay
with Tb3+
(A) The Fluorescence spectra of Tb3+FRET where the signal decreases as Gd3+ competes
the terbium out of hProCA32. (B) The fluorescence intensities at 545 nm were plotted
against the concentration of Gd3+fitted using the one-to-one binding Equation 2-5 λEx= 288
nm, λEm= 545 nm.
5.2.6. Determining Zn2+ binding affinity of hProCA32 using a FluoZin-1 competition
assay
As discussed earlier, in chapter 3, zinc is another physiological metal that might be
expected to bind to our contrast agent causing Gd3+ to be released freely in the body. This can
lead to lethal toxicity in normal physiological functioning. Hence, it is extremely important to
evaluate the binding affinity of hProCA32 for Zn2+. The experiment was performed using the
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aforementioned procedure in Section 2.9. The zinc-binding affinity of hProCA32 was
determined by competition assay with 1 μM Fluozin-1 and 1 μM of Zn2+ in10 mM HEPES pH
7.2. As the contrast agent was titrated into the system, the fluorescence intensities decreased,
indicating that the contrast agent was successful in grasping the zinc from the dye. The
experiment was performed in triplicate and fluorescence intensity versus wavelength was
graphed as shown in Figure 5.10 A. The fluorescence intensity maxima at 519-520 nm was
averaged for three trials and used to fit the curve to obtain K app as shown in Figure 5.10 B. The
Kapp for this competition assay, 2.07 μM, was used to calculate the Kd using the following
equation (derivation shown in Section 2.9):

𝑲𝒅𝟐 = 𝑲𝒂𝒑𝒑 𝑲

𝑲𝒅𝟏

𝒅𝟏 +[𝑭𝒍𝒖𝒐𝒁𝒊𝒏−𝟏]𝑻𝒐𝒕𝒂𝒍

Equation 5-4

The binding affinity of hProCA32 for Zn2+ is 1.42 ±0.18 × 10-6 M, which is comparable
to the binding affinity of rat ProCA32 as shown in Table 5.1in section 5.3.
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Figure 5.10 Determining Zinc binding affnity of hCA32.
(A) Competition assay with 1 μM FluoZin-1 and 1 μM zinc in 10 mM TrispH 7.2 and
hProCA32 titrated in increasing concentration to determine the Kd, Excitation at 495 nm
and Emission range : 500- 650 nm (Three trials) (B) Fitted curve with the maximum
intensity at 520 nm versus the concentration of hProCA32 titrated in to the system
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Figure 5.11 Determining Lutetium binding affnity of hProCA32.λEx= 288 nm, λEm= 546 nm
10 μM hProCA32, 20 μM Tb 3+ in 10 mM HEPES 150, mM NaCl, pH7.2
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5.2.7. Serum stability of hProCA32

The acceptability of a contrast agent depends on its metal stability and relaxivity. As
seen in the earlier sections, hProCA32 demonstrates improved metal selectivity over other
physiological metals such as Ca2+ and Zn2+with high gadolinium binding affinity and relaxivity
as compared to other commercially available contrast agents. Thus, with such remarkable
qualities, hProCA32 can be a promising and potential MRI contrast agent. In order to achieve
this goal, it is extremely important to test the in vivo stability of the contrast agent. Testing the
stability implies on the in serum activity and its interactions with proteins and enzymes present
under biological conditions. It is crucial for our contrast agent to maintain its intact structure and
has no interactions with enzymes that can possibly cleave it. In order to study the stability of
hProCA32 without PEGylation and improvement caused after PEGylation, 500 μM of both
contrast agents were incubated at 37°C in 50 % serum with twice the amount of gadolinium (1
mM) for 12 days. Samples were collected at various time points during the 12 days and
examined via SDS-PAGE, Ponceau red staining and western blot (Figure 5.12, Figure 5.13 and
Figure 5.14). hProCA32 remained stable in the serum for at least 8 hours as confirmed by SDS –
PAGE, and Ponceau red staining of the membrane used for western blot. The cysteine PEGylated
hProCA32 remained stable until 12 days where the lysine PEGylated hProCA32 remained stable
until 8 hours. Western blot is sensitive and the antibodies used specifically binds to the protein
and can be trapped on a film. However, the western blot shows unwanted serum bands as well.
This can be justified with several possibilities: The contrast agent has some interactions with the
proteins present in serum, the serum contains some proteins that can be identified by the antibodies, the improper washing of the membrane after adding secondary antibodies could be
enhanced by the substrate added prior to filming the membrane.
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* Note: All the samples added
to gel electrophoresis are of
equal volume.

Figure 5.12 The serum stability study of hCA32 at 37°C in presence of gadolinium.
(A) The Ponceau red staining of the membrane used for western blot, (B) The 15 % SDSPAGE and (C) The western blot corresponding to the membrane used for ponceau red
staining for the samples before and after incubation in serum at 37°C.

The serum stability test performed on hProCA32 indicates that the protein is stable at
least up to 8 hours after incubation. Rat ProCA32 is stable in serum until 12 days [39] and
hProCA32 is also expected to show similar behavior. Many factors affect the outcome of such
lengthy experiment such as the sample collection and preparation methods, in addition, the tubes
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where the samples are stored should be tight enough to avoid any evaporation of the samples.
The outcome of these experiments could be improved by increasing the amount of protein and
optimizing the appropriate conditions for preparing the samples for SDS-PAGE.

Figure 5.13 The serum stability study of Cysteine PEGylated -hCA32 at 37°C in presence
of gadolinium.
(A) The Ponceau red staining of the membrane used for western blot, (B) The 15 % SDSPAGE and (C) The western blot corresponding to the membrane used for ponceau red
staining for the samples before and after incubation in serum at 37°C
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The sample for protein only has 3 bands, suggesting that some of the protein indeed
PEGylated (Lane 3 in Figure 5.13 A and C). The bands at 12 kDa and 26 kDa are the monomer
and dimer forms of the non PEGylated protein, respectively. Ponceau red staining and western
blot confirm that the protein is stable until 12 days as clear bands are seen at around 15 kDa.
Furthermore, SDS-PAGE shows that the protein degrades after 5 days of incubation; however,
the samples collected on the following days show clear bands at 15 kDa until 12 days. This could
have been due to an error in preparing that particular sample.
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(A) The Ponceau red
staining of the membrane
used for western blot, (B)
The western blot
corresponding to the
membrane used for ponceau
red staining for the samples
before and after incubation
Figure 5.14 The serum stability study of Lysine PEGylated-hProCA32 at 37°C in presence
of gadolinium.
Multiple bands between 12 kDa to 25 kDa are the bands corresponding to the protein
PEGylated at multiple sites. The Ponceau red staining of the membrane prior to washing with
antibodies suggests that the protein remained stable until 8 hours of incubation whereas the
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western blot shows the protein remained stable until 3 days of incubation in serum at 37 °C in
presence of gadolinium.
5.2.8. Magnetic Resonance imaging of cysteine PEGylated hProCA32 and Future
Directions
In order to assess the ability of the protein as an imaging contrast agent with in vivo
functioning, hProCA32.cys-2kDa cys-PEG was injected into mice implanted with a human
cancer and MRI imaging performed by Dr. Shenghui Xue, using a 4.7 T Varian MRI scanner at
Emory University. Since rat ProCA32 does not have any grafted targeting moiety, it is reported
to enhance mostly the liver region [39]. Therefore, 5 mM of the contrast agent was injected via
tail-vein injection into the mice, and MRI images were scanned at various time points using
gradient echo and fast spin echo sequences. Gradient echo gives T1 weighted enhanced images
whereas fast spin echo provides T2 weighted dark images. The T1 weighted images seen in
Figure 5.15 show images before injection of contrast agent and after the injection of contrast
agent. From these images, it can be concluded that the contrast agent dramatically enhanced the
kidney and liver region after 15 minutes of injection. After 40 minutes of injection, the contrast
agent seems to be distributing out of the kidney into the blood vessels. The kidney and liver
region still shows some enhancements after 2 hours of injection. The contrast agent showed not
only positive bright T1 weighted images but also demonstrated negative, dark T2 weighted
images. As seen in Figure 5.16, the liver region is light before injection of the contrast agents,
however after the injection of our contrast agent liver region appears even darker. Considering
the positive preliminary enhancements, it can be concluded that hProCA32 not only fulfills
essential requirement of being a contrast agent but also can definitely be a suitable candidate.
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Kidney

Liver

Figure 5.15 T1 weighted- Gradient echo sequenced MRI images of kidney and Liver before and after injection of
hProCA32.cys-2kDa PEG.cys into the mice via tail vein injection,
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Figure 5.16 T1 weighted- Fast spin echo sequenced MRI images of Liver before and after injection of hProCA32.cys-2kDa
PEG.cys into the mice via tail vein injection.
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5.3. Conclusion and Future directions

In this chapter, the overall biophysical properties of hProCA32 as a contrast agent have
been investigated. The site-specific conjugation of hProCA32 to cys-PEG reagent at C-terminal
cysteine has been successfully attained using various lengths of PEGs. The gel electrophoresis
results confirm that the contrast agent has been conjugated with PEG with more than 90 %
efficiency. The PEGylated contrast agents are further characterized by its biophysical properties
and functioning. The average r1 and r2 relaxivity of hProCA32 are 27 mM-1 s-1 and 36 mM-1 s-1,
respectively, which are close to rat ProCA32 with r1 and rr2 of 30 mM-1 s-1 and 40 mM-1 s-1,
respectively[39]. The rat ProCA32 expressed in large culture volume by fermenter has r1 and r2
relaxivities of 24 mM-1 s-1and 33mM-1 s-1(Figure 5.4A and B). To provide more concrete
evidence for our hypothesis “conjugation with PEG causes an increase in relaxivity”, further
investigation is required.
The metal binding affinities of hProCA32 to Tb3+ and Ca2+ were tested using metal
chelator buffer system to tightly control the free metal in the system. The Gd3+ binding affinity
of hProCA32 determined by competition assay with Tb3+ was about 10-22 M, which is
comparable with Tb3+-DTPA. In overall, the Gd3+ binding affinity of hProCA32 was larger than
Zn2+ and Ca2+ binding affinities (Figure 5.5, Figure 5.9 and Figure 5.10). These data are
comparable with rat ProCA32 (Table 5-1). In terms of metal selectivity, Log (KGd/KCa) of
gadolinium over zinc and calcium is significantly higher as well (Table 5-1). This suggests that
hProCA32 will bind to Gd3+ with significantly higher affinity than to the physiological metals
such as zinc and calcium. Contrast agent should bind to Gd3+ strongly to reduce toxic effects
generated by the accumulation of free gadolinium in the body especially kidney.
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Furthermore, the human serum stability of hProCA32 and PEGylated hProCA32 at 37°C
showed that non-PEGylated hProCA32 is stable at least 8 hours after incubation. The
conjugation of PEG indeed improved the stability of our contrast agent up to 12 days whereas;
the lysine PEG conjugation improved the stability up to 3 days confirmed by Western blot. For
more concrete conclusion, further optimization of experimental conditions is required.
Subsequently, to establish the in vivo functionality of hProCA32 as a contrast agent, gradient
echo sequence (T1 weighted) and fast spin echo sequence (T2 weighted) of MRI images were
taken using 4.7 T MRI Varian scanner. Gradient echo sequence suggests that our contrast agent
clearly shows enhancements in kidney and liver after 15 minutes of injection. In summary,
hProCA32 has high metal affinity, selectivity and stability with 10 times higher relaxivity as
compared to the commercial contrast agent, Gd-DTPA.
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Table 5.1 The summary of the Kd values of hProCA32 to Tb3+, Gd3+, Ca2+ and Zn2+ using
various metal binding assays such as metal chelator buffer system (Tb3+,Gd3+ , Ca2+ ) and
competition assay using molecular probe FluoZin-1 dye for Zn2+ .

Kd (M)

Gd-DTPA (M)

3+

Tb

-22

9.55 × 10
3+

Gd

-21

-21

-22

-22

3

2.59 ± 0.1 x 10

-10

-9

-8

6.00 ± 2.0 × 10

-8

4

3.57 ± 0.01 × 10
-19

6.31 × 10

-21

2

2.48 × 10

2.79 ± 0.36× 10

1.51 × 10

2+

Zn

hProCA32 (M)

1.21 ± 0.33 × 10

1.86 × 10

2+

Ca

ProCA32 (M)

1.35 × 10
-6

5

1.42 ± 0.18 x10

Lu3+

N/A

N/A

4.23 x 10-22

Log (KGd/KCa)

10.9

13.1

13.72

Log (KGd/KZn)

2.5

14.3

15.34

2

This dissociation constant was determined using DTPA-Tb3+ buffer system in 10 mM HEPES,
150 mM NaCl, 0.1 μM Rhod-5N pH 7.2 and dependent on the binding affinity of the chelatorTb3+ Ex =288 nm and Em = 545 nm
3
This dissociation constant was determined using a competition with Tb3+ in 10 mM HEPES,
150 mM NaCl. Ex =288 nm and Em = 545 nm
4
This dissociation constant was determined using DTPA-Ca2+ buffer system in 10 mM HEPES,
150 mM NaCl, pH 7.2. Ex =280 nm and Em = 311 nm
5
Dissociation constant determined using competition with FluoZin-1 (1 μM FluoZin-1 and 1
μM zinc in 10 mM Tris PH 7.2)Ex= 495 nm and Em = 516-520 nm
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6. OVER ALL CONCLUSION AND SIGNIFICANCE OF THIS WORK
MRI is a powerful diagnostic tool that is non-invasive with deep tissue penetration. MRI
can provide detailed information about tissues and organs without utilizing any harmful
radiations. Due to low sensitivity, contrast agents are mostly used to enhance MRI images. In the
past decade, Dr. Jenny J. Yang’s lab has adopted and merged the idea of MRI contrast agents
with excellent knowledge of protein chemistry and developed novel class of Protein based MRI
contrast agents (ProCA). ProCAs can not only improve the low sensitivity with their dramatic
contrasting ability but also target the specific cancer biomarkers for early detection of cancerous
tissues using MRI. The first generation of ProCA was developed by constructing a Gd3+ binding
site on a stable scaffold protein, domain 1 of rat CD2. ProCA1 demonstrated 10 times higher
relaxivities as compared to the clinically used MRI contrast agents. High relaxivity, directly
corresponds to the use of low dosage, and low toxicity. Furthermore, targeted ProCA1 proved to
be excellent molecular imaging probe against breast cancer. During this process, a series of
ProCAs were developed with even more improved in vivo properties.
ProCA32 containing two metal binding sites is thermo-stable and has excellent solubility
and most importantly the production process is relatively easy. ProCA32 is known to accumulate
in the liver when injected into mice and dramatically enhances the liver region when observed
under MRI scanner. Thus, to further advance to the next stage of pre-clinical studies, rat based
ProCA32 must be humanized to reduce the immunological effects when injected into the human
body. The objective of this thesis is to optimize the production in the bacterial system and
examine functional and biophysical properties of hProCA32. There are several questions need to
be addressed for isolation of hProCA32 obtained from E.coli expression system. 1) What are the
optimal expression conditions for the large-scale production of hProCA32?, 2) What are the
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optimal conditions for the cost effective and time efficient purification of hProCA32 and how to
isolate in its purest form under industrial set up?, 3) Does hProCA32 differ from rat ProCA32 in
terms of its structural properties, metal binding affinities, metal selectivity, and stability and
relaxation properties as a MRI contrast agent?, 4) How to reduce the possible in vivo
immunogenicity effects generated by our contrast agent? 5) Can modification of hProCA32 with
PEG improve it’s in vivo stability, solubility, bio-distribution and biocompatibility without
disrupting the functioning of hProCA32? 6) Can site- specific cysteine PEGylation be applied to
hProCA32 to attain homogeneity? 7) How different is hProCA32 from the cysteine PEGylated
hProCA32 and which length of PEG is best suitable for the in vivo application with altering its
metal-binding properties?
One of the major findings in this thesis is that hProCA32 and its variants can be
successfully expressed and purified using the bacterial system. The optimal expression can be
achieved using both BL21 (DE3) and BL21 (DE3).pLySs competent cells at reduced
temperatures after induction. In purification process, boiling the soluble hProCA32 supernatant
indeed showed the removal of major unwanted proteins. Furthermore, the protein was
successfully isolated from nucleic acids using 3 % streptomycin and affinity column with a
maximum final yield of about 32 mgL-1. In addition, hProCA32 can be isotopically labeled with
15

N using M9 minimal medium. Labeled hProCA32 with 15N can be used for lanthanide binding

studies using NMR as a future direction.
Another major finding is for metal binding studies, which suggests that hProCA32 has
high binding affinity for Gd3+ with dissociation constant of 10-22 M as compared to the other
physiological metals such as calcium (10-8 M) and zinc (10-6 M). The metal selectivity Log
(KGd/KCa) of hProCA32 for Gd3+ is higher over calcium (Log (KGd/KCa) = 13.72) and zinc (Log
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(KGd/KZn)= 15.34). Various fluorescence metal binding assays were tested to develop an indirect
metal binding assay. The relaxivity remained relatively comparable with rat ProCA32 with r1 of
27 mM-1s-1 and r2of 36 mM-1s-1.

Cysteine PEGylated hProCA32 showed excellent serum

stability at 37 °C up to 12 days. However, these are preliminary results and must be repeated to
draw any concrete conclusions. Furthermore, 2 K cysteine PEGylation of hProCA32 showed T1
weighted enhancements and T2 weighted properties when introduced into mice under MRI
scanner. Another finding, suggests that hProCA32 can bind to trivalent Lu3+ with a dissociation
constant of 10-22 M, which proposes a possible application for our contrast agent in SPECT.
All these significant findings are supportive of hProCA32’s functional similarities with
rat ProCA32 and it is evident that hProCA32 can prove to be a great candidate for future
molecular targeting. The long-term goal is to optimize the stability by using suitable PEG length,
which does not disrupt the physical properties and enhances the relaxation properties of
hProCA32. Additionally, the binding ability of hProCA32 with other metals such as Gallium,
Yttrium, Zirconium and Indium can be tested as future direction for its application in nuclear
medicine imaging modalities such as combined PET/MRI.
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